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The Cognitive, Attitudinal, and Behavioural Responses of the Elderly to Print DTC 




 Pharmaceutical companies have adopted a pull marketing strategy of prescription 
drugs as part of their marketing mix. This approach referred to as Direct-To-Consumer 
Advertising (DTCA) where drugs are directly advertised to the consumer through mass 
media, has been the topic of an ongoing debate. While advocates of DTCA defend its 
educational value, opponents question its safety, especially when addressing a market 
segment presumed to be vulnerable (i.e., the elderly).  
 Based on previous research that demonstrated the dependence of advertising 
message persuasiveness on a number of individual factors, this thesis investigates the 
elderly’s responses to DTCA, across variations in their prescription drug use, health 
status, and cognitive abilities. How do users (vs. non-users) of prescription drugs, and 
older consumers with high (vs. low) cognition, differ in their post-exposure attitudes 
towards the ad and advertised brand, in their ad recognition, and behavioural intentions? 
 The findings suggest that prescription drug users are more receptive of DTCA and 
more willing to act in response to it. However, all participants regardless of their health 
status were resistant to changing their doctor, if he/she refused to prescribe the advertised 
drug to them. Also, consumers with a high cognition level better recognized the ad’s 
claims, engaging in a benefit/risk trade-off in their processing of the ad information. The 
results further suggest that sufferers who do not use a prescription drug do not differ in 
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their post-ad-exposure attitudes and behavioural intentions than non-sufferers. Finally, 
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In the past, consumers learned about a medicine only through an encounter with a 
medical professional. Today, they are bombarded with drug advertisements on television 
and radio, in newspapers and magazines, and on the Web. This study attempts to 
investigate consumer reactions to this type of advertising referred to as Direct-To-
Consumer Advertising (DTCA), in response to the lack of consumer research on DTCA 
voiced by Huh, Delorme, and Reid (2004), and Sheffet and Kopp (1990). 
The present study attempts to examine all three elements of the hierarchy of 
effects paradigm concurrently. To further explain, advertising activates three different but 
sequentially related effects: cognitive, affective, and behavioural (DeLorme, Huh, and 
Reid 2006a). Four dependent variables corresponding to the different measures of DTCA 
effectiveness discussed by Menon et al. (2004) were chosen to that end. 
Examining the receivers’ encoding of the drug-related information is crucial in 
assessing the effectiveness of an ad.  Hence, the respondents’ recognition of the ad’s 
content is measured as an indication of its cognitive effects. In addition, consumers’ 
attitudes towards the ad and towards the brand illustrate their emotional and evaluative 
responses, knowing that “feelings contribute uniquely to attitude toward the ad, beliefs 
about the brand’s attributes, and attitude toward the brand” (Edell and Burke 1987). 
Finally, with consumers’ cognitive and attitudinal responses subsequently determining 
their behaviour, the respondents’ behavioural intentions are also measured.  
The study was initially conceived as an experimental study, but due to unforeseen 
developments was recast as exploratory. The level of risk disclosure and participants’ 
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involvement in the ad were initially projected as a message characteristic and an 
individual variable respectively, which interact in moderating consumers’ post-ad-
exposure responses.  
Previous research showed that consumers’ hierarchy of responses are also 
moderated by several individual and pre-dispositional factors, such as their prescription 
drug use and health status. Moreover, the receivers’ cognitive abilities influence their 
processing and learning of the ad information. Building on these findings, an exploratory 
analysis suggested that consumers’ prescription drug use, their health status and their 
cognition level were important variables. 
The elderly constituted this study’s target sample as they are a large and 
substantial market segment. Their increased consumption of prescription drugs, 
combined with their increased use of mass media, and uncertainty regarding DTCA, 
renders this research more relevant (Huh et al. 2004). 
Finally, this exploration has important contributions to marketers and policy 
makers. Armed with its findings, they will be able to fine-tune drug advertising 
regulations. As Davis and Meader (2009) note in their evaluation of an ad’s fair balance, 
policy makers should assess consumers’ post-exposure reactions, in addition to analyzing 










 The following is a review of the literature and findings that are relevant to the 
current study. An overview of DTCA and of the controversy around it is accompanied by 
an account of the FDA regulations regarding mass media drug advertising. The purposes 
of and effectiveness measures specific to this type of advertising are also related. Next, 
the issues pertaining to the differential risk perceptions formed by a DTCA audience are 
reviewed. In an attempt to gain better knowledge of consumers’ reactions to risk 
information, fear appeal theories are then presented and applied to the context of risk 
disclosure in DTCA. Given that receiver characteristics influence the processing and 
attitude formation towards an ad, characteristics pertaining to the elderly population are 
also explored. A focus is directed at their information processing abilities, vulnerability to 
persuasion, and the effect of specific pre-dispositional and demographic factors.  Various 
message characteristics and situational factors that may influence the effectiveness of an 
ad are also considered. Finally, the different conceptualizations of the involvement 
construct are introduced, in addition to its antecedents and consequences. 
 
A. OVERVIEW OF DIRECT-TO-CONSUMER ADVERTISING  
Before the advent of DTCA, physicians were the primary targets of 
pharmaceutical companies, and assumed the role of the gatekeeper in the manufacturer-
doctor-consumer triad. Companies relied on personal selling that involves professional 
detailing and dispensing drug samples, alongside advertising in medical journals, and 
through direct mail and the Web. Conventions and Continuing Medical Education (CME) 
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modules, designed to offer expert advice on a drug, were common promotional strategies 
as well. In 1997, the FDA relaxed its regulations regarding mass media advertising, 
which accelerated the proliferation of DTCA. This type of advertising, which builds 
brand name recognition, also arose as a result of the strong competition amid prescription 
drugs, exacerbated by that of generic drugs, and in response to the growing consumer 
need for better health-education (Finlayson and Mullner 2005; Foley 2001; Holmer 
1999).  
 
1. Types of DTC Ads 
There are three different types of DTC advertisements (Morgan 2007). Disease-
awareness ads, as their name indicates, briefly inform consumers about a specific 
ailment, and invite people to subsequently discuss existing treatments with their doctors, 
without mentioning any drug name. Reminder advertisements include only general 
information about the drug (i.e. name, dosage, and price). Since they do not display any 
benefit information, such ads are not required to mention the drug’s side effects. The 
most common type of direct ads is product-claim advertisements, which constitute the 
focus of this study. This is the only type regulated by the FDA, as it mentions the drug’s 
brand name, accompanied by benefit and risk claims (i.e., contraindications, side effects, 
precautions).  
In addition to stating the drug’s side effects, broadcast product-claim 
advertisements are required to provide consumers with four additional sources of 
information (a toll-free number, concomitantly running brochures, a website and 
physician consultation), a regulation referred to briefly as adequate provision (Frosch and 
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Grande 2010; Morgan 2007; Roth 1996).  The adequate provision, among many other 
regulations, emerged in an attempt to establish a safety of advertising drugs directly to 
consumers, a concern raised by many critics of DTCA. 
 
2. Debate over DTCA 
DTCA has been criticized as having interfered with the learned intermediary 
doctrine, where the prescribing physician was the only informed gatekeeper of 
prescription drug information that consumers could turn to (Parker and Pettijohn 2005). 
Physicians now deal with unlearned consumers rather than patients, consumers who no 
longer need to communicate with a doctor to learn about a drug, and who are willing to 
insist on a prescription, disregarding its physician-judged inappropriateness (Hollon 
1999; Mehta and Purvis 2003). This change in the dynamics of the relationship between 
the healthcare provider, patient and manufacturer, is at the root of the debate concerning 
the correctness and safety of DTCA. 
With consumers acting as confident specialists, DTCA revealed itself to be a double-
edged sword: it averts a deficient intake of drugs while molding an overly drug-
consumerist society (Donohue, Cevasco, and Rosenthal 2007). DTCA has also been 
blamed for generating a rise in drug costs, justified by the need to compensate for the 
increase in advertising expenditures (Baukus 2004; Frosch and Grande 2010; Mehta and 
Purvis 2003). 
Proponents of DTC prescription drug advertising describe it as informative and 
educational (Foley 2000; Macias and Lewis 2003); raising consumers’ awareness and 
knowledge about a drug or disease; and empowering them in independently managing 
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their health (Finlayson and Ross 2005; Holmer 1999; Maddox 1999).  In their view, 
DTCA also slightly contributes to enhancing patient compliance with a prescription 
(Frosch and Grande 2010; Macias, Lewis, and Baek 2010). Conversely, DTCA has been 
condemned by its opponents as being deceptive and misleading, especially as most 
consumers lack the knowledge required to correct a false claim, and do not question the 
unreliable information presented in ads (Finlayson and Ross 2005; Mehta and Purvis 
2003). 
A misleading statement can be developed in many ways: through presenting 
unapproved/unproven claims or data from an unreliable study; through selectively stating 
minor side effects and ignoring major ones; and through disguising statistical results, for 
example (Donohue et al. 2007). 
 
3. FDA Regulations 
The FDA attempts to regulate prescription drug ads by making sure 
pharmaceutical companies present balanced and accurate risk and benefit information 
(Frosch and Grande 2010). As Macias et al. (2010) and Roth (1996) state, risk 
information should be clearly legible and visible in the advertising message, and should 
be accompanied by a ‘brief summary’ stating the side effects, precautions and 
contraindications of the drug, in consumer-friendly language. 
It is important to note that balance is attained in several ways: 1) through 
equalizing the number of benefit and risk claims; 2) by adopting a similar physical 
presentation (i.e., noticeable font size and location, color, etc.); 3) by fairly reflecting the 
drug’s pros and cons, without subtly downplaying the side effects and overemphasizing 
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the benefits. In this study, balance was attained by balancing the number of the drug’s 
benefits and side effects. The above regulation applies to both print and broadcast DTCA, 
and its implementation is enforced by the FDA through the Center for Drug Evaluation 
and Research (CDER) unit that has the power to claim financial penalties from firms 
violating the regulation (Altizer 2009).  
One objective of the present study is to contribute to the improvement of policy 
making concerning a direct marketing strategy, and its proper targeting of a sensitive 
market segment, the elderly. However, it is also important for marketers to balance the 
concerns about legalities with the probability of promotional success, determined by the 
various factors discussed below. 
 
4. Profile of Drugs Promoted Through DTCA 
According to Frosch and Grande (2010), and Kavadas (2003), the best candidates 
for DTCA are drugs that have a large potential market, and hence, are worth being 
advertised directly to consumers (e.g., lipid lowering agents). The effectiveness of DTCA 
also depends on the drug’s side effects and on the complexity of the ailment. A lengthy 
ambiguous list of side effects might further decrease the comprehensiveness of any 
complicated ailment addressed in the ad. Therefore, DTCA is most suitable for 
“medications that have a brand name patent protection used to treat chronic conditions 
with few or mild side effects” (Polen, Khanfar, and Clauson 2009).  
The success and end-result of a DTCA campaign vary depending on the stage of 
the drug’s life cycle. With the help of a pull marketing strategy, the introduction of a new 
drug is accelerated, while consumer loyalty towards a mature drug is maintained before it 
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goes off-patent (Morris, Mazis, and Brinberg 1989; Roth 1996). In assessing the success 
of a pharmaceutical advertising campaign, it is important to examine specific indicators 
pertaining to DTCA effectiveness. 
 
5. Mapping DTCA Effectiveness 
Menon et al. (2004) proposed a DTCA effectiveness model, in which they present 
effectiveness measures that are specific to the context of DTCA, some of which are the 
focus of the present study (See Figure 1). The suggested model is grounded on the 
hierarchy of effects paradigm, which was first proposed by Lavidge and Steiner (1961). 
They considered that the receiver goes through five steps of advertising information 
processing before purchasing, which consist of the following: awareness  knowledge 
 liking  preference  conviction. Therefore, when exposed to an ad, message 
receivers are moved through what Menon et al. (2004) label a series of psychological 
states, starting with “cognition, then affect and conation.” Huh and Becker (2005) also 
highlight the importance of this paradigm and of the information processing perspective 
in studying the effectiveness of advertising. They refer to the above mentioned 
psychological states as “a number of response steps.”  
  Based on that, and given that the consumer first forms a cognitive perception of 
the ad-that includes awareness and knowledge of the featured brand-the authors suggest 
recall and recognition as key measures of the comprehensiveness of a DTC ad. In other 
words, the ability of a drug ad to stimulate knowledge and comprehension of its content 
is an indication of its effectiveness.  
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Other indicators or key measures, pertaining to the affective element of the 
hierarchy of effects, are the consumers’ attitudes towards the ad and brand. These 
attitudinal measures refer to the evaluation a message receiver has formed vis-à-vis an 
advertising message and brand. MacKenzie and Lutz (1989) found that attitude towards 
the ad strongly influences attitude towards the brand, which in turn influences purchase 
intentions.  
Finally, information search, drug inquiry and request behaviours are indicators of 
the behavioural outcomes of an ad exposure, and consequently, of the ad’s ability to 
move consumers to act in response to it. “Information search behaviour is widely 
acknowledged as an integral element of the consumer decision-making model,” and is 
extremely important in the context of DTCA, knowing that mass mediated drug ads are 
required to include references for additional information on the drug. Measuring drug 
inquiry and request behaviours is also vital, while keeping in mind that the final authority 
with regards to deciding on the purchase of the advertised drug lies in the hands of the 











FIGURE 1. TRADITIONAL INDICATORS OF AD EFFECTIVENESS AND DTC 
AD EFFECTIVENESS 
 






















Source: Menon et al. (2004) 
Note: * DTCA effectiveness measures that are relevant to the current study. 
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6. Comparison of Broadcast, Print and Online DTCA 
This section briefly reviews the pros and cons of each medium, because “the 
characteristics of the media in which DTC ads are carried, influence consumer processing 
of the advertising messages” (Choi and Lee 2007). 
While televised drug ads remind consumers of a drug, print ads fills the lack of 
information left behind by their counterparts. Because of their fast and instant nature, 
television ads do not satiate the consumers’ need for detailed knowledge about the 
product. These “sound bites of information” are insufficient to accurately and 
comprehensively disclose risk information (Abernathy and Adams-Price 2006). The 
physical product itself (i.e., the drug) cannot be easily visually differentiated from others, 
in contrast to most consumer products. This absence of  distinctiveness or what Liebman 
(2001) labels as lack of “package recall,” in the midst of a clutter of ads, partially leads to 
lower product recognition, and drug name recall.  
Print ads, however, may benefit consumers in that they are more thorough and 
accessible to them at their own pace and convenience. One can always go back to an ad 
in a magazine or newspaper and scrutinize the message content. Yet, the format of a print 
drug ad might hinder its clarity; the presentation of the package insert that is highly rich 
with technical medical information might render the ad confusing, especially for older 
people who are slower than the young at encoding a message content (Abernathy and 
Adams-Price 2006). Consequently, the ambiguity of such ads might decrease their 
“memorability.” Hence, print ads, alongside televised ads, face the possibility of being 
ineffective at increasing recall, and knowledge of a drug.  
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Another objective of this study is to further examine the potential reasons 
underlying a low recognition level of print ads, despite their internally controlled pace.   
Marketers might be puzzled when deciding what medium to use; however, the ultimate 
option is a multi-media campaign, including online advertising. Drug websites are 
considered to be a “persuasive educational tool [that builds] credibility, image, and 
consumer trust,” rather than a marketing tool (Maddox 1999). Consequently, they aid in 
closing the “expertise gap between patients and providers, [but] only to a certain extent,” 
since older adults still prefer to engage in mutual decision making with their doctors (Xie 
2009). The author’s findings are supported by Maddox’s (1999) study. The latter advises 
marketers to sustain their advertising to professionals, because some specific segments of 
the population (i.e., females and older people), despite them referring to DTCA for 
increased information about an ailment or treatment, rely on health care providers when it 
comes down to decision making. Hence, a synergistic DTCA campaign should be 
accompanied by the conventional advertising to physicians. 
Regardless of the chosen advertising medium, marketers are required to 
communicate the drug’s side effects. To better achieve that end, factors affecting 









B. RISK INFORMATION 
Informing consumers of a drug’s risk is essential for the fair balance criteria and 
may therefore engender favourable evaluations of the ad. In contrast, encouraging 
processing of risk information may be counterproductive and lead to an increase in 
learning the drug’s risks, paralleled by a decrease in acquiring its benefits (Menon et al. 
2004; Morris et al. 1989).  
It is crucial to understand consumers’ perceptions of risk information, and capture 
how and why such responses are formed, in order to design more effective ads. 
To begin, why is risk information in drug advertisements given special and higher 
attention than safety notices of consumer goods? Castagnoli (1998) clearly answers this 
question by pinpointing how “the consequences of misuse of prescription drugs are 
potentially quite serious” as they might not only affect “the quality of a patients’ life, but 
in many instances, they affect life itself.” Hence, it is no surprise that the FDA attempts 
to enforce the fair balance regulation in DTCA, whereas advertisers often try to dilute the 
side effects and contraindications of a drug. 
 
1. Consumers’ Unfamiliarity with Health Care: A Source of Fear 
Consumers are actively involved in deciding for their health and well-being, as 
well as manufacturers are potentially liable for deceptive promotion of drugs. It is now 
more challenging for the latter to design ads that are informative and comprehensive and 
yet not threatening. This situation is aggravated by the nature of the message receivers, 
who are uninformed and lack the necessary knowledge to process such information 
objectively and holistically. This is supported by Tucker and Smith’s (1987) findings that 
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consumers favor general rather than specific information, and by Morris et al.’s (1989) 
findings that consumers engage in a “trade-off” when processing information. An 
increased amount of risk information will generate an increase in the amount of risk 
information recalled, and a decrease in that of benefit information recalled. 
Hence, advertisers are caught in a vicious circle, between complying with the 
advertising regulations and satisfying the consumers’ right for truthful and ethical 
advertising on one hand, and not frightening them on the other hand. 
Consumers’ unfamiliarity with health care might distort their perceptions of risk 
information and interfere with an objective analysis of the drugs’ side effects. There are 
many other factors as well that may be related to the presentation of side effects that 
affect their acceptance. 
 
2. The Presentation of Side Effects 
Message characteristics related to the presentation of side effects may moderate 
consumers’ processing of the risk information in the ad and subsequently influence their 
acquisition of the message content, and evaluation of the ad and brand.  
Specific risks, for example, are perceived to be “more interesting and adult-
oriented” (Morris, Ruffner, and Klimberg 1985). However, they increase consumers’ 
learning of risk information as they provide a context that enhances the elaboration of 
their meaning, hence their vivid character and arousing nature. By varying the number, 
structure and prominence of warning messages, Morris et al. (1989) determined the 
influence of such factors on consumers’ awareness of benefit and risk information. 
Intuitively, a higher number of side effects raises consumers’ concern. The perceived 
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severity of side effects, their order, and mode of presentation (print or oral) can also 
influence consumers’ attitude towards the ad and brand, and the evaluation of the fair 
balance criteria (Davis and Meader 2009). 
 Determining how various disclosure approaches might moderate the processing of 
information is vitally important in evaluating an ad’s effectiveness. Also, the assessment 
of consumers’ responses and interpretation of the ad’s content are as important as content 
analysis, in evaluating the ad’s fair balance (Davis and Meader 2009).  
This research borrows from theories of fear appeal to justify the cognitive, 
emotional, and behavioural responses of the elderly to risk disclosures. The following is a 
review of the literature on fear appeals. 
 
3. Fear Appeals 
The effectiveness of ads is partially determined by their ability to persuade the 
consumer to buy the product. Fear appeal theorists suggest that the communication of 
information regarding the advertised product should be accompanied by some form of 
arousing stimulus that is essential to produce a change in the consumer’s purchasing 
behaviour (Henthorne, Latour, and Nataraajan 1993). 
 
 3.1 Definition. Fear appeal ads are defined as “a type of psychoactive ad which is 
capable of arousing fear in the viewer regarding the effects of the viewer’s suboptimal 
lifestyle” (LaTour, Snipes, and Bliss 1996). In turn, a psychoactive ad is “an emotion-
arousing ad which may cause recipients to feel extremely anxious, to feel hostile toward 
others or to feel a loss of self-esteem,” (Benet, Pitts, and LaTour 1993).While fear-based 
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ads display the frightening consequences of refraining from using a product, DTC ads 
evoke the fear in taking the advertised drug due to its potential side effects. 
 
 3.2 Application to the Context of DTCA. Fear appeal ads and DTC ads are similar 
in the anxiety they might engender in the audience. Therefore, based on this similarity, 
fear appeal theories may be applied to predict and justify consumers’ rejection of DTC 
ads. 
 DTC prescription drug ads are inculcated with the intention to inform the 
audience of the potential side effects associated with taking the drug. However, as 
previously mentioned, partially due to the audience being an unlearned receiver of DTCA 
information, risk information can be just as disturbing and as arousing as fear appeals. 
Another analogy can be established, this time between specific and general risk 
information versus a high and low level of fear stimulus in that both specific side effects 
and high fear appeals are perceived as irritating and are overwhelming (Keller and Block 
1996; Tucker and Smith 1987). Subsequently, similarly to fear appeals, a great amount of 
risk disclosure may trigger consumers’ defense mechanism in trying to cope with such 
threatening information. 
 These defensive responses include “avoiding the message, minimizing the 
severity of the threat, selectively attending the message, discounting the threat, and 
denying its personal relevance” (Keller and Block 1996). When a receiver of the message 
resorts to any of these techniques, he/she will not elaborate on the message content, thus 
weakening its persuasive assets and rendering the ad ineffective. The arousal of anxiety 
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in the recipient of the message is the element that sparks off the adoption of the above 
described resistance techniques (LaTour et al. 1996).  
 
3.3 Thayer Arousal Model. Henthorne et al. (1993) further explain the process of 
fear awakening, drawing from the Thayer Arousal Model. This model distinguishes 
between weak and strong fear appeals; the former elicits energy-activating feelings of 
tension in the receiver. This kind of energy is positive as it induces the receiver to attend 
more to the message and elaborate on it.  
In contrast, the latter (strong fear appeals) elicits anxiety-activating feelings of 
tension. The resulting anxiety arousal consumes a lot of energy from the receiver, a 
negative energy that is dissipated in trying to adjust to the overwhelming message. 
There is hope for marketers however, as there is an optimal level of arousal, that results 
from a threshold of fear appeal and does not threaten the message persuasiveness. 
However, going beyond this optimal threshold will generate negative feelings and will 
lead the receiver to seek refuge under the umbrella of avoidance techniques (Henthorne et 
al. 1993). 
 While it is relevant to determine the threshold level related to risk disclosure in 
DTCA, pharmaceutical marketers first need to recognize consumers’ responses to such 
information. According to Morris et al. (1985), consumers label a high level of risk in 
DTC ads as irritating. This finding is the thread that links risk disclosures to fear appeals, 
as a high level of both is perceived as irritating. Hence, even though both are defined 
differently, they are both prone to produce anxiety in the receiver.  
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Therefore, in this study, participants who are exposed to a high level of risk 
disclosure are expected to become anxious, retain less information from the ad, exhibit a 
negative attitude towards the ad and brand, and refuse to behaviourally respond to the ad.  
LaTour and Zahra (1989) contend that there is no universal threshold level of fear, 
and that “other elements of the individual’s cognitive structure are at work, resulting in 
individual uniqueness in reactions to fear stimuli,” or, to risk information. Several 
individual psychological differences that might moderate consumers’ responses to a 


















C. ADVERTISING TO THE ELDERLY 
“[…] the effectiveness of a communication is dependent on understanding who 
said what to whom, how and with what effect” (Menon et al. 2004). In other words, 
characteristics of the source, message, channel, and of the receiver, are predictors of 
DTCA effectiveness. Therefore, characteristics of the elderly audience pertaining to their 
information processing, vulnerability to persuasion, and demographic variables are 
reviewed next. The effect of message characteristics on their responses to DTCA is also 
examined. 
 
1. Information Processing 
 Research has demonstrated that older and younger consumers differ in their 
perceptions of threat, and in their reactions towards persuasive advertising efforts, 
including DTCA (Benet et al. 1993; DeLorme et al. 2006a). These differences have been 
attributed to variations in the psychological and cognitive characteristics of both age 
segments. 
 
 1.1 Processing Speed and Source Format. The elderly are slower than the young 
at processing information due to a declining central nervous activity (Abernathy and 
Adams-Price 2006; Benet et al. 1993; DeLorme et al. 2006a, 2006b; Phillips and 
Sternthal 1977; Roedder John and Cole 1986). Therefore, they encounter a reduction in 
their short term memory capacity as reflected through difficulties at learning and using 
new information, in both print and television formats (Cole and Houston 1987).  
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 In contrast, Phillips and Sternthal (1977) and Roedder John and Cole (1986) 
indicate that when exposed to a self-paced medium such as a magazine or a newspaper, 
the elderly do not display a weakened ability to learn or comprehend information, since 
the rate at which the information is presented does not magnify their diminished 
processing speed. On a similar note, Benet et al. (1993) indicate that the elderly are able 
to encode information accurately if given time. Hence, they consider that this age 
segment only appears to have decreased intelligence resulting from a decline in their 
processing efficiency (vs. ability), especially when they adopt a strenuous learning 
strategy. In sum, the authors reject the stereotype of the “senile senior citizen.”  
 The literature has revealed a discrepancy in findings regarding the moderating 
role of the source format (print or broadcast) on the magnitude of elderly’s processing 
deficits. In addition, it has revealed an inconsistency regarding this segment’s motivation 
to process branded drug advertisements. 
 
1.2 Active versus Passive Processing. Many researchers agree that younger people 
have a higher disposition to retain advertised drug information, than older people do 
(DeLorme et al. 2006a, 2006b; Foley 2001; Foley and Gross 2000). However, in the 
context of DTCA, older consumers are more at risk for having a health problem than 
younger consumers, and consequently have higher information needs. Their greater 
involvement results in a more active processing of health information and an increased 
attention to DTCA content (Huh et al. 2004). Various studies (Choi and Lee 2007; 
Maddox 1999; Morris et al. 1986; Perri and Nelson 1987) support this reasoning as they 
found that older people are more prone to pay attention to DTCA, and subsequently 
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behaviourally respond to it. Huh et al. (2004) argue that support for this speculation is 
provided by Mehta and Purvis (2003), who found higher recall levels of print advertising 
in older female consumers [45 years old and above], as compared to younger females 
[35-44 years old]. However, the authors fail to note the confounding effect of gender, 
with females being inherently more involved with DTCA than males. 
On the other hand, the elderly’s interest in gathering health information from 
mass media does not replace their preferred reliance on professionals in health-care 
decision making. Benet et al. (1993) cite Botwinick (1978) when referring to this 
segment’s heightened wariness and calculated steps in its decision making. “[…]The 
elderly are less likely to challenge medical authority or to press physicians for detailed 
information about medical conditions” (DeLorme et al. 2006a).Consequently, they might 
exert less effort at elaborating on and learning advertising content than the young, 
knowing in advance that they will passively comply with their physician’s 
recommendations. As one 83-year old male participant self-reported, “I don’t pay any 
attention to it….I got my doctor’s okay and that’s good enough for me” (DeLorme and 
Huh 2009). 
The results of Foley’s (2000) study also indicate that older and less educated 
consumers pay less attention to the information provided in DTC ads, and do not fully 
derive benefit from its accessibility. They nevertheless do not converse with their doctor 
to fill their lack of knowledge about a prescription drug, which plunges them in a 
“medication information gap” or what Xie (2009) calls “the expertise gap.” 
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This study will attempt to answer the inconsistency of previous findings regarding 
the elderly’s inclinations in health care decision making by examining the persuasiveness 
and moving power of DTCA. 
 
1.3 Processing Strategies and Recognition. In the face of these mixed results 
regarding the older consumers’ processing motivation of mass media drug advertising, 
two things are certain; the elderly suffer from deficiencies in their use of memory 
strategies, specifically encoding and retrieval strategies. The former relates to the storage 
and registration of information in memory while the latter relates to accessing the stored 
information. The elderly face limitations in semantic encoding strategies that can inhibit 
their recall and recognition of information when compared to the young (Roedder John 
and Cole 1986).  In addition, they face a memory search deficit, which impedes their 
acquisition of new material when coupled with their failure to use efficient organizational 
strategies for encoding incoming information.  
The cognitive difficulties faced by the elderly aggravate their susceptibility to 
promotional persuasive attempts, a topic that is explored next. 
 
2. Consumer Related Vulnerability 
 DeLorme and Huh (2009) mention that the unique product nature of drugs is a 
factor that contributes to the elderly’s psychological vulnerability to persuasion and to 
their apprehensiveness vis-à-vis DTCA, when paired with their cognitive deficits and 
lack of professional health knowledge. Therefore, the elderly are believed to exhibit more 
sensitivity to overwhelming persuasive messages than do younger adults (Balazs, 
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Yermolovich, and Zinkhan 2000). However, the authors later refute such claims and 
consider the elderly’s vulnerability an exaggerated statement. In their view, the elderly 
actively and critically evaluate advertising messages and are not more easily persuaded 
by DTCA than younger consumers. The former seem aware and conscious that DTC 
advertisements are inculcated with the pharmaceutical companies’ financial interests and 
an intention to persuade them to buy the product. They also are intrigued by the ads’ 
technical and information-rich content and their exaggerated efficacy claims. And since 
in general, people thrive to project a positive self-image-that includes being a hard target 
to the media’s persuasive attempts-the elderly effortlessly try to deliberately resist the 
influence and moving power of advertising stimuli. However, they perceive others as 
being less immune to these attempts in what is called a third-person effect framework or 
the indirect (vs. direct) effects approach (Gunther and Storey 2003). 
 Taken from a different perspective, Benet et al. (1993) argue that this segment’s 
consumer-related vulnerability might not be deemed applicable to the highly educated 
baby boomers when they reach the age of 65, and grow into the majority of the senior 
market. 
 The present study will also attempt to fill the disparity in research, pertaining to 
the vulnerability to persuasion of the elderly segment. In order to meet this objective, it is 
essential to examine the effect of pre-dispositional and demographic factors on 






3. Pre-dispositional and Demographic Intervening Factors 
 As revealed by the literature, older consumers’ anxiety when dealing with drug 
information is justified by their lack of trust in their unprofessional health knowledge. It 
is also exacerbated by their ineptitude at seeking information, and their decreasing mental 
and processing abilities. It hence follows that the respondents’ age, gender and education 
level, their health status/prescription drug use, and their attitude towards DTCA, are pre-
dispositional and demographic factors that among others, are related to their cognitive, 
emotional and behavioural responses to DTCA. 
 
 3.1 Age. Benet et al. (1993), in their study, “caution against grouping all 
individuals over 65 into a single market segment.” The authors also specify that the 
elderly do not encounter a reduction in their intellectual abilities until late 80s. In their 
view, the effect of aging on the physical and mental capabilities reveals itself as 
significant only on those aged 85 or more. Along the same lines, Davis and French 
(1989) consider that “the elderly are the most heterogeneous segment of the population, 
differing from one another more than any other age group.”  
 
3.2 Gender and Education.  The demographic factors of gender and education 
were also measured, as they might determine consumers’ learning behaviour regarding 
health information (An 2007). Zoeller (1999) reported the results of a DTC advertising 
audit run by Scott-Levin (a pharmaceutical consulting firm), in which a female 
preference for readership of print health information supplemented by a discussion with 
their physician was noted. Females hold a more positive attitude towards DTCA, justified 
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by their increased involvement in health care decision making (Huh et al. 2004). 
Subsequently, they are more likely to engage in drug requests and seek drug information 
(Huh and Becker 2005). The same behavioural outcomes apply to higher educated 
consumers who consider themselves as having the necessary education that enables them 
to independently engage in confident decision making. Williams and Hensel (1995) in 
turn found a negative relationship between one’s education level and his/her attitude 
towards DTCA.  
 
3.3 Health Status and Drug Use. Consumers’ health status was also measured as 
it could influence their involvement level, with sufferers being more involved than non-
sufferers (Kavadas 2003). Perri and Dickson (1988) found an effect of DTC ad exposure 
on drug inquiry behaviour, moderated by one’s health condition. In addition, DeLorme 
and Huh (2009), and Williams and Hensel (1995) observed a negative relationship 
between one’s health, and his/her interest in a DTC advertisement. Perceived health was 
also negatively related to attitude towards DTCA, in Huh et al.’s (2004) study, and to 
information seeking and drug inquiry behaviours, in Huh and Becker’s (2005) study. 
 On the other hand, Mehta and Purvis (2003) found that prescription drug users, 
and those related to a drug user, exhibited a more favorable attitude towards DTCA. Both 
seemed more involved with the ad, which translates into higher readership levels, and 
higher recall levels of ads. They also were more inclined both to inquire about and insist 
on a drug in an encounter with a medical professional. However, the generalization of 
their findings to a male sample is questionable. In addition, Alperstein and Peyrot (1993) 
found that regular drug users were more likely to attend to DTC ads than non-users.  
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 3.4 Attitude towards DTCA. Those who favorably respond to DTCA are more 
inclined to read drug ads, inquire about, or request an advertised drug (An 2007; Mehta 
and Purvis 2003). Therefore, a trusting attitude in DTCA seems positively related to 
advertising-based decision making. Hence, being an antecedent to their buying intentions 
and to shaping their attitudes towards the ad and brand, consumers’ attitude towards 
DTCA and towards print advertising were measured as potential covariates (An 2007). 
 
 It is important to note here that the effect of the above mentioned audience 
characteristics on the elderly’s behavioural responses depends first and foremost on their 
perception of DTCA as an important information source; or on the previously mentioned 
third-person effect (DeLorme et al. 2006b). In other words, “the impact of the ads on 
consumers should be moderated by the attitudes the consumers hold to DTC advertising; 
of particular importance is trust in DTC advertising,” as stated by Huh and Becker 
(2005). For example, if a sufferer does not believe in the credibility of DTCA or attempts 
to resist its influence by projecting it on a third-person, he/she will not become involved 
in the persuasive message and will refute what is expected from a sufferer. 
   
4. Message Characteristics and Situational Factors 
 Apart from the above mentioned receiver characteristics that might influence the 
effectiveness of DTCA, there are various message characteristics and situational factors 
that might hinder an effective communication of an advertising message. Generally 
speaking, older consumers regard drug advertising as useful because it expands their 
knowledge and decreases their uncertainty regarding a drug. However, complicated and 
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busy advertisements containing inconsistent and doubtful information revive consumers’ 
initial uncertainty (DeLorme and Huh 2009). This uncertainty raises negative emotional 
responses, especially in those who are in short of the necessary coping skills that will 
help them mitigate their insecurity and indecisiveness regarding an advertised drug. 
These negative affective responses in turn serve as an impetus for the actions of older 
consumers, who will resort to uncertainty management strategies, such as seeking 
additional information (i.e., doctor consultation), or educating themselves on DTCA 
regulation (DeLorme and Huh 2009).  
 Furthermore, Roedder John and Cole (1986) suggest that, apart from the 
information format (i.e., television or print), the information quantity or overload can 
exacerbate the effect of the elderly’s slower processing speed, and limited memory 
strategies. The inclusion of the traditional drug package insert in the ad, also overburdens 
the receiver for it involves a great amount of technical language. The same applies to 
complex visual images and diverting backgrounds that may impede the older adults’ 
retrieval of the ad’s copy points.  In sum, when task-such as reading an advertisement- 
involves “deliberate, self-initiated processing, integrating context or inhibition,” the 
receivers’ processing efficiency is likely to decrease (Abernathy and Adams-Price 2006). 
That is why branded drug ads should be “created and developed with the information 
processing abilities of the elderly in mind.” 
 The objective of the present study is to experimentally determine how different 
levels of risk information and ad involvement (respectively considered both a message 
characteristic and an individual variable), might differentially affect the respondents’ 
learning of the ad’s information and thus shape their behaviour and attitudes towards the 
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ad and brand. The previous analogy made between a high level of risk and fear appeal is 
supported by the study conducted by DeLorme and Huh (2009), in which participants 
expressed their need for a clear communication of drug risks yet in a “nonthreatening 
matter so they know how to interpret and act on the information.” In their study, the 
respondents described high risk ads as irritating, and stimulating “anxiety, distress, fear 
and anger,” leading them to “[…] just basically tune out.” 
 In general, it is expected that a high level of risk disclosure will induce tension in 
the receiver and consequently trigger his/her defense mechanism. With regards to 
involvement, it is a factor that will determine to what extent the elderly receivers will be 
motivated to scrutinize and evaluate the ad information (Christensen, Ascione, and 
Bagozzi 1997). Branded drug ads were found to generate more favorable attitudes and 
exert more influence when the receivers were highly involved (Perri and Dickson 1988).  













D. ADVERTISING MESSAGE INVOLVEMENT 
 There appear to be no signs of a universally accepted conceptualization or 
measurement of the involvement construct. However, there is consent that “involvement 
[is] an important moderator of the amount and type of information processing elicited by 
a persuasive communication” (Petty, Cacioppo, and Schumann 1983). It therefore has an 
impact on the effectiveness of an ad.  
 Krugman (1965) originally conceptualized involvement as “the number of 
conscious bridging experiences, connections, or personal references per minute that the 
[receiver] makes between his own life and the stimulus,” at the time of encoding. In 
situations where an object is judged as personally relevant, the individual will exert 
greater cognitive effort at learning the object-related message, and consequently make 
more associations with it. These associations might be revived in memory at the time of 
purchase. The definition used by Krugman (1965) accentuates the role of personal 
relevance as a fundamental characteristic of the involvement construct, a notion that was 
salient throughout different conceptualizations of involvement; these are reviewed next. 
 
1. Involvement as an Elaborative Process 
 Greenwald and Leavitt (1984) define audience involvement as “the allocation of 
attentional capacity to a message source, as needed to analyze the message at one of a 
series of increasingly abstract representation levels.” It follows in their opinion that 
involvement operates on a continuum, with an ascending order of required attention 
capacity for each level. The levels of the continuum range from pre-attention where the 
individual’s responsiveness is triggered unconsciously, to focal attention, comprehension, 
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and elaboration. In the final stage, deliberate attention and conscious processing occur, as 
the receiver tries to incorporate the incoming information with his/her existing 
knowledge. A highly involved person will reach the final stage and voluntarily exercise 
an effort at generating cognitive inferences about the stimuli, developing as such an 
enduring emotional and behavioural response to it.  
 
2. Involvement as a Personal/Situational Construct 
 In contrast to Greenwald and Leavitt (1984), Petty et al. (1983) do not adopt an 
elaboration process model. They rely on their Elaboration Likelihood Model of 
persuasion (ELM) which distinguishes between the central and peripheral processing 
routes and assumes a trade-off between both. Involvement is an important moderator of 
the route to persuasion, determining whether argument-based or peripheral-based 
processing will occur. To further explain, highly involved individuals will embark on the 
central route, and “diligently, actively and cognitively [assess] information central to the 
particular evaluation” (Inman, McAlister, and Hoyer 1990). On the other hand, low 
involved individuals will have a low likelihood of elaboration, and therefore process 
information using the peripheral route, grounded on the simple inferences or contextual 
cues (i.e., music, pictures, etc.) in the persuasion context, rather than on the message 
arguments. The change in behaviour resulting from the central route approach is due to 
persuasion linked to the arguments of the message and their quality, while that resulting 
from the peripheral route is due to the reliance on message heuristics or decision rules 
(Christensen et al. 1997). For example, low involved individuals will interpret a 
persuasive message as credible simply because an expert source (cue) is communicating 
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the message. It is important to note here that argument-based persuasion might lead to a 
behaviour change, while peripheral persuasion will only result in a volatile and fragile 
attitude formation. 
 Previous Knowledge. It is also vitally relevant to consider the intervening role of 
previous knowledge which has noticeably re-emerged in many studies, and is emphasized 
by Celsi and Olson (1988). The authors also talk about felt involvement to suggest the 
motivational and relative nature of the construct. They refer to involvement as the 
“consumer’s overall subjective feeling of personal relevance.”  From their point of view, 
consumers develop domain knowledge, by accumulating and storing information about 
objects and issues that are relevant to them. Domain knowledge is activated when the 
stimulus is of importance to the consumer. Subsequently, the consumer is motivated to 
attentively consider and elaborate on the stimulus information, to form an evaluative 
response. On a similar note, Sujan (1985) proposed that one’s familiarity with, and 
previous knowledge about the product class, enhance the processing of the stimulus-
related information.  
 Although the present study’s questionnaire did not include a measure of the 
participants’ domain knowledge regarding arthritis prescription drugs, it measured their 
health status (i.e., whether they suffer from arthritis and use a prescription drug for it). It 
is reasonable to assume that such measures are suggestive of the respondents’ product 
class knowledge, to a limited extent. 
 Moreover, it is noteworthy to mention Zaichkowsky (1985, 1994) who developed 
the Personal Involvement Inventory, a measure of the involvement construct. For the 
purpose of scale development, the author defined involvement in her more recent study as 
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“a motivational construct which partly relies on the antecedent factor of the person’s 
values and needs.” 
 
3. Involvement as an Attention Construct 
 Gardner, Mitchell, and Russo (1985) also point out that the processing of an ad is 
influenced by our knowledge stored in memory, and define involvement as “a situation 
specific state variable with components, intensity and direction.” Intensity refers to the 
level of attention allocated to the stimulus-related information, whereas direction refers to 
the processing strategy employed by the consumer. The authors distinguish between two 
types of processing strategies. An individual scoring high on his/her interest in a product 
will engage in a brand processing strategy, by elaborating more on the provided 
information, and extrapolating inferences and counterarguments about the product’s 
performance, based on an evaluation of its attributes. The use of a non-brand processing 
strategy consists of the opposite, and applies to low involved individuals, who do not 
fully initiate their brand schema, and develop a scattered brand knowledge. Evoking a 
non-brand processing strategy involves focusing on the basic elements of the ad, its style 
and form (i.e., brand name, object, visual images, etc.), similar to Petty et al.’s (1983) 
peripheral processing route. The consequences tied to executing a brand processing 
strategy consist of faster and greater recall and recognition levels, which subsequently 
facilitate the retrieval of product information at the time of purchase. A peripheral 
processing strategy resulted in more positive attitudes towards the brand, due to a 




4. Involvement Framework 
 The literature review clearly revealed that research has been inconsistent vis-à-vis 
the conceptualization of involvement. These discrepancies have laid down the ground for 
Andrews, Durvasula, and Akhter’s (1990) work. The authors consider involvement to be 
an “individual, internal state of arousal with intensity, direction and persistence 
properties.” The personal relevance of the message plays an important role in 
determining the intensity of arousal (Park and Young 1986).  The direction of 
involvement designates the stimulus (e.g., issue, product, advertisement) towards which 
the arousal is routed; in this study, involvement is directed towards the ad. 
Persistence refers to the durability of the involvement, which recognizes that a greater 
state of involvement will be more enduring and stable. Wine connoisseurs provide an 
example of enduringly involved individuals. 
In their attempt to synthesize previous research, Andrews et al. (1990) developed 
a framework for the conceptualization and measurement of the involvement construct, 
based on the commonalities and inconsistencies found in earlier studies (See Figure 2). In 
their framework, they distinguish between the antecedents, consequences, and the state of 
involvement itself, contrary to other authors who confoundedly defined involvement in 








Figure 2. Andrews, Durvasula, and Akhter’s (1990) Framework for the 
Conceptualization and Measurement of the Involvement Construct 
 
 
                                                
                           
  
 
    
 Source: Kavadas (2003) 
 
For instance, while other researchers consider the personal relevance of the stimuli to be 
an indicator of the individual’s level of involvement, the authors consider it an antecedent 
that will determine his/her state of involvement. In addition, in contrast to Greenwald and 
Leavitt (1984) who consider involvement in itself to be an elaboration process, Andrews 
et al. (1990) and Mitchell and Olson (1981) treat it as a variable influencing the type of 
processing. In other words, the elaboration process is perceived as a consequence rather 
than an indicator or integral element of the involvement state.  
The antecedents and consequences of involvement are further explored next. 
 
4.1 The Antecedents of Involvement. According to Laurent and Kapferer (1985), 
knowing the sources of involvement is extremely important in understanding the 
“consumer’s subjective situation” and in recognizing how he/she should be approached in 
an advertising communication. The antecedents revolve around two major categories: 
one’s personal needs, goals and values, and situational or decisional factors, which Celsi 
Antecedents: 
Personal needs, goals 


















and Olson (1988) label as intrinsic and situational sources of personal relevance (ISPR 
and SSPR), respectively.  
ISPRs are “relatively stable, enduring structures of personally relevant knowledge 
derived from past experience and stored in long term memory.” They are distinguished 
from domain knowledge (knowledge about a product class stored in memory) in that they 
comprise one’s cultural values, the degree to which the object fulfills one’s desired self-
image, and personality factors such as need for cognition, among others. Celsi and Olson 
(1988) note that ISPRs affect consumers’ motivation to be attentive to and understand the 
message, while domain knowledge impacts their ability to process the information. In 
addition, ISPRs influence involvement the most when an object is perceived as fulfilling 
one’s desires and goals. 
Situational factors on the other hand, include the perceived risk of making a 
purchase decision, the purchase occasion, and the use of the object, among others. Sales 
promotions act as situational factors or sources of felt involvement, as they temporarily 
trigger important goals in the consumer, such as saving money. In this particular purchase 
situation, a consumer’s felt involvement with the product is expected to increase, but be 
of transitory nature, decreasing again when the consumer’s goal is attained. 
 
4.2 The Consequences of Involvement. Previous research has demonstrated that 
the consequences of involvement pertain to the hierarchy of effects discussed previously. 
“Different levels of involvement are associated with different sequences of impacts on 
the familiar attitude components of affect, behavior, and cognition” (Greenwald and 
Leavitt 1984). For instance, deeper processing of a communicated message results in 
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greater long-term recognition of its content. In addition, variations in involvement 
influence the number and type of inferences drawn, the use of deep encoding strategies 
and subsequently, the robustness and persistence of persuasion that is predictive of 
behaviour.  
“In theory, involvement is considered an individual difference variable. It is a 
causal or motivating variable with a number of consequences on the consumer’s purchase 
and communication behavior” (Laurent and Kapferer 1985). Therefore, the current study 
primarily aims at investigating the consequences of involvement by elderly consumers, 
with a main focus on their information processing motivation. In essence, highly involved 
individuals will exert a greater effort at assimilating an ad’s message and encode more 
associations in their mind. Hence, highly involved individuals are expected to recognize 
more information than low involved individuals. The involvement variable is also 
expected to interact with the risk level of the ad, in influencing consumers’ responses. 
For purposes of simplicity, involvement is defined as “the motivational state of an 
individual induced by a particular advertising stimulus or situation” (Laczniak, Muehling, 
and Grossbart 1989). It is reasonable to assume that prescription drug users are engaged 
in an enduring involvement that “reflects a general and permanent concern with the 
product class,” herein arthritis prescription drugs (Laurent and Kapferer 1985). In 
general, this source of involvement is linked to objects that are perceived by the 
consumer as self-defining and fulfilling of his/her core values and needs.  
Also, it is possible that the effect of product class involvement might interfere 
with the advertising message involvement manipulation. Hence, it might be difficult to 
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get a person who is not interested in the product class to be highly involved in the ad, and 
vice versa (Laczniak et al. 1989).      
 
            In conclusion, the literature review revealed what DeLorme and Huh (2009) 
summarized in one study. Through conducting in-depth interviews with participants aged 
65 to 83, they identified the following four sources of DTCA uncertainty: 
1) DTCA content-related uncertainty which pertains to the previously discussed 
effect of message characteristics.  
2) Consumer-related uncertainty which results from the demographic and pre-
dispositional characteristics of the elderly. 
3) Pharmaceutical and advertising industry-related uncertainty which relates to the 
elderly’s attitude towards DTCA, and their limited trust in pharmaceutical 
companies. 
4) And finally, government regulation and health-care system-related uncertainty, 
which results from consumers’ lack of confidence in governmental or 
organizational regulatory actions.  
These uncertainties are unveiled in the present study through an examination of the 










 The original research questions centered around the relationship between the 
amount of risk information disclosed in the ad and the elderly’s recognition of the ad’s 
claims, their attitude towards the ad and brand, and their behavioural intentions ,while 
controlling for the role of advertising message involvement (See Appendix A for initial 
research questions). Therefore, the study was initially intended as a 2 (involvement: high 
vs. low) x 3 (risk disclosure: high vs. low vs. balanced) between-subjects factorial design, 
yielding a total of six experimental conditions (for a description of the involvement and 
risk manipulations, refer to Appendices B and C). However, as the research unfolded, an 
experimental design was no longer possible. Although the pretests revealed significant 
manipulation checks (Appendix D), the risk disclosure and involvement manipulations 
checks of the actual experiment were insignificant (Appendix E), rendering an 
experimental analysis impossible. Due to these unforeseen developments that transpired 
during data analysis, the literature review was revisited to look for appropriate theoretical 
constructs in building upon the data collected, and the data were appropriately mined 
based on the foundations established in the literature. The study therefore took an 
exploratory direction and the research questions were revised. 
The literature review revealed that “involvement does not systematically lead to 
the expected differences in behavior. They depend on the antecedents of involvement 
[…]” (Laurent and Kapferer 1985). In addition, past research has established that 
prescription drug use-which is an antecedent of involvement in the context of the present 
study-is a significant predictor of consumers’ responses to DTCA. Moreover, it is well 
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acknowledged by the literature that cognition mediates the elaboration of information and 
thus influences information processing (Gunter 1998). High cognitive abilities for 
example, are expected to aid the elderly in their acquisition of the ad content.  
 Based on the above foundations in the literature, the study went on an exploratory 
path, with research questions related to the effect of cognition and prescription drug 
utilization, on respondents’ attitude towards the ad (Aad), attitude towards the brand (Ab), 
recognition, and behavioural intentions. 
Therefore, considering the above, the following research questions are addressed: 
 
RQ1:  Does prescription drug use have a differential effect on consumers’ 
attitude towards the ad and brand, recognition of the ad’s content, and 
behavioural intentions?  
RQ2:  Does cognition level have a varying influence on consumers’ 
processing of the message, and subsequently on their emotional, and post-
exposure behavioural intentions? 
 
In addition, suffering from arthritis does not necessarily entail using an anti-
arthritic prescription drug. Therefore, the sample consisted of three groups with three 
different health statuses: those who suffer from arthritis and use a prescription medication 
as a remedy, those who suffer from arthritis and do not use a prescription medication for 
it, and those who do not suffer from arthritis. Moreover, previous research has 
determined a negative relationship between one’s health status and attitude towards 
DTCA and behavioural intentions. Consequently, an interest in examining the differential 
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effect of one’s health status (e.g., whether they suffer from arthritis, and if they do, 
whether they use a prescribed medication for it) on their responses to a DTC ad led to the 
following research question: 
 
RQ3:  How do arthritis sufferers who use a prescription drug (SUFF.USERS), 
arthritis sufferers who do not use a prescription drug 
(SUFF.NONUSERS), and non-sufferers of arthritis (NON-SUFFERERS), 




















A.  SAMPLE CHARACTERISTICS (See Table 1) 
 A total of 90 English-speaking elderly individuals, aged 65 or above, composed of 
61 females and 29 males, participated in the study. The average age was 73, and ranged 
from 65 to 95 years. Approximately 54 % of the sample suffer from arthritis, and 31 % 
received an arthritis prescription drug at one point in their life. Approximately 49 % of 
the sample scored low on the Digit Symbol Substitution Test (description of instruments 
used is provided next).   
Table 1: Descriptive Statistics of the Sample 
























16 5 2 23 11 7 - 18 
Total  37 15 9 61 19 10 - 29 
Rx. Users 
(31%) 












9 13 8 30 7 7 - 14 
Note: Percentage figures relate to the total sample (e.g., 62 % of the total sample are middle old, 54% of the total sample suffer from 
arthritis, etc.). 
The middle old are aged between 65 and 74, seniors are aged between 75 and 84, and the very old are aged 85 or above, following 
Lazer’s (1986) segmentation. 
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B. QUESTIONNAIRE  
 Two subtests, the Vocabulary Test and the Digit Symbol Substitution Test 
(DGST) were taken from the Wechsler Adult Intelligence Scale (WAIS) (2008) and 
served as cognitive measures. The former is part of the Verbal Comprehension Index and 
measures crystallized intelligence (which refers to one’s knowledge base, and remains 
stable with age). The Vocabulary Test therefore assesses the degree to which one has 
learned, been able to comprehend, and verbally express vocabulary. In contrast, the 
DGST is part of the Processing Speed Index and measures fluid intelligence, which refers 
to one’s ability to learn new information, an ability that decreases with age. It is a test of 
figural relations, assessing the participants’ speed of visual perception by asking them to 
substitute a symbol for a random succession of numbers, in a limited time.  
 Since reading an advertisement involves learning and utilizing new information, 
the DGST was considered as a more suitable indication of the respondents’ cognitive 
abilities. Therefore, the participants’ cognition was dichotomized into high and low levels 
using a median split of their scores on the Digit Symbol Substitution test. 
The first section of the questionnaire intended to measure the involvement 
manipulation using Zaichkowsky’s Personal Involvement Inventory (1985). Five out of 
20 items were chosen based on their relevant applicability to the study (See Appendix G). 
A seven-point bipolar scale was used, with a score of one and seven indicating low and 
high involvement respectively. The involvement score for each participant consisted of 
the average of the five items.  
Following, a risk manipulation check asked participants to assess the riskiness and 
safety of the drug, with a value of one indicating they perceived the drug to be more 
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risky/unsafe than beneficial/safe, and a value of seven indicating the opposite (See 
Appendix G). 
 
1. Measurement of the Dependent Variables (See Appendix H) 
Previous research has established that the elderly suffer from learning 
deficiencies. However, the magnitude of these deficits is moderated by the type of 
measurement chosen (Cole and Houston 1987; Roedder John and Cole 1986). Therefore, 
an optimal response format, a recognition test (vs. a recall test), was chosen as a measure 
of the respondents’ acquisition of the ad content. In a recall format, respondents are asked 
to open-endedly bring to mind what they have been exposed to, while in a recognition 
format, they are quizzed on the advertising content they have seen. The former does not 
account for the retrieval deficits experienced by both the young and elderly adults, and 
might lead to a floor effect across conditions. It should be mentioned that “recognition 
tests may demonstrate a much greater registration of copy points and brand names on the 
part of young and elderly consumers than do recall tests” (Roedder John and Cole 1986). 
The number of risk and benefit statements correctly recognized from the target ad 
constituted the recognition measure. Participants were presented with 10 statements 
drawn from the target ad’s content, five related to the drug’s selling points and five 
related to its risks. Respondents were asked to indicate whether the statements are true or 
false. A “don’t know” category was added to decrease guessing. 
Attitude towards the ad (Aad) refers to the receivers’ evaluation of the 
advertisement. It has a direct influence on purchase intentions, which highlights its 
relevance as a measure of ad effectiveness (Mitchell and Olson 1981). The Aad measure 
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consisted of Holbrook and Batra’s (1987) scale. The final Aad score for each respondent 
was the average of four seven-point bipolar items. 
Attitude towards the brand (Ab) refers to one’s perceptions of the brand 
featured in the ad. The Ab measure consisted of Laczniak and Muehling’s (1993) scale. 
The final Ab score for each respondent was the average of five seven-point bipolar items. 
Everett’s (1991) scale served as a measure of behavioural intentions. One 
question tackled consumers’ willingness to read the advertisement, five questions 
touched on their intention to ask a doctor for additional information, and three questions 
examined their willingness to search for more information through other sources 
(e.g., 1-800 number, drug website, family or friends). A value of one meant that 
respondents definitely would not display the proposed behaviour, while a value of five 
meant they definitely would display the proposed behaviour. 
 
2. Covariates and Demographic Data  
Attitude towards advertising in print media was measured using Shavitt, Lowrey 
and Haefner’s (1998) scale, which consisted of 13 questions scored on a five-point 
bipolar scale (See Appendix J). 
In measuring attitude towards DTCA, Perri and Nelson’s (1987) scale was 
employed. Respondents had to strongly agree or strongly disagree on six items, scored on 
a five-point bipolar scale (See Appendix J). 
 Demographic data were gathered in the last section on the participants’ age, 
gender, first language, and education level. Respondents also had to indicate whether 
they suffer from arthritis, whether they take an anti-arthritic prescription drug, whether 
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they were related to someone who suffers from this ailment, and whether they worked in 
the health care field (See Appendix I). 
 
C. FORMAT OF THE ARTHRAID AD 
The target ad was specifically developed for the purpose of this study. The benefit  
and risk information presented in the ad was drawn from real advertisements (See Figure 
3 in Appendix C). However, the drug name Arthraid was fictitious in order to control for 
drug familiarity effect. The picture, displaying two older adults walking at the beach, was 
intended to communicate the effectiveness of Arthraid in soothing arthritis pain and 
helping the elderly gain back an energetic lifestyle. Arthritis was the chosen ailment, 
because it is non-emotional, and common among female and male adults. That is not to 
mention that anti-arthritic drugs are one of the most heavily advertised. 
 The ads had a similar layout and design with the body copy displayed on the 
bottom half of the page, under the picture. The pictures were in black and white, and the 
body copy had the same font size across all ads except for the drug’s name in the target 
ad, which was somewhat larger. The booklet displayed a total of four ads, including three 
filler ads and one random version of the three target Arthraid ads placed the third. 
 
D. PROCEDURE 
 A convenience sample (n=60) from the Concordia Longitudinal Retirement 
Project (within the Concordia Department of Psychology) was recruited by phone. The 
remaining (n= 30) was recruited from senior centers that included the Notre-Dame-de-
Grace Senior Citizen Council and the Contactivity Centre. Throughout 21 sessions, up to 
 46 
 
six participants were first told that the researcher was interested in the elderly’s responses 
to DTC prescription drug advertising. Participants were also informed of the approximate 
duration of the experiment (30 minutes), and of their right to know the results of the 
study once data collection was completed. After signing the consent form (See Appendix 
F), the participants completed the cognitive measures. Next, they were given an ad 
booklet with the involvement manipulation on its cover page. After browsing through the 
ads at their own pace, participants were given instructions on how to complete the 
questionnaire. Then, they answered the post-exposure questionnaire without referring 
back to the ad booklet. Originally, random assignment to the conditions was employed. 
However, it is no longer possible to use the group assignments for purposes of the 
exploratory data analysis. 
 During the sessions, the researcher responded to any questions and made sure 
participants did not refer back to the ad booklet while answering the questionnaire. At the 
end, respondents were debriefed, thanked and given $15 as a compensation for their time 













A. REVISED FRAMEWORK 
 As previously mentioned, the research framework had to be revised based on the 
foundations in the literature. The literature review revealed that one’s goals, needs and 
values determine his/her level of involvement. Sufferers and prescription drug users, for 
example, were found to exhibit a higher level of ad involvement.  In addition, Sujan 
(1985) proposed that one’s familiarity with and previous knowledge about the product 
class affect the processing of the stimulus-related information. Therefore, the 
participants’ use of an arthritis prescription drug and their health status were considered 
as potential independent variables.  
 Furthermore, cognition was also regarded as an independent variable, since the 
elderly’s processing abilities are an audience characteristic that differentially affects their 
responses to a message or stimulus. Changes in cognition, motivation, and emotional 
processing also affect older adults’ decision making (Xie 2009). Consequently, the 
present study has taken an exploratory direction in an attempt to address the following 
research questions:  
 RQ1: Does prescription drug use have a differential effect on consumers’ attitude 
towards the ad and brand, recognition of the ad’s content, and behavioural 
intentions?  
RQ2: Does cognition level have a varying influence on consumers’ processing of 





In order to better determine the behavioural intentions of the participants, a factor 
analysis was conducted on the questions pertaining to behavioural intentions, using the 
principle component analysis as the factor extraction method and the Varimax rotation as 
the rotation method (See Table 2). 
Table 2: The Rotated Component Matrix of “Behavioural Intentions” 
Factor 1 Factor loading        Cronbach Alpha 
Discuss drug’s effectiveness with doctor 0.763  
 
0.807 
Ask Friends about advertised drug 0.808 
Call 1-800 0.814 
Visit drug’s website 0.776 
Factor 2   
Request Arthraid 0.702 0.474 
(correlation coefficient) Change doctors  0.874 
 
The first factor of the behaviour measure refers to additional information seeking 
from other sources. This type of behaviour is important in the context of DTCA since 
referring consumers to other information sources is a fundamental recurrent element in 
prescription drug ads (Menon et al. 2004).  As Huh and Becker (2005) mention, 
“basically, what consumers are expected to do after viewing prescription drug ads is to 
seek information and talk to others.” Given that the correlation coefficient of “Request 
Arthraid” and “Change doctors if he/she refused to prescribe Arthraid to me” is low 
(r=0.474), and given the importance of both behaviours as an outcome of  DTCA, both 
will be considered in data analysis, as separate behavioural measures. “Request Arthraid” 
independently indicates drug request intentions (a participant’s willingness to ask their 
doctor for a prescription of the advertised drug). “Changing doctors” independently 
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indicates the participants’ willingness to consult another physician in case the former one 
challenged their insistence on Arthraid.  
 The following data analysis examines the effect of the participants’ prescription 
drug use and level of cognition on their recognition of the ad’s claims, their Aad and Ab, 
and their behavioural intentions (e.g., additional information search behaviour, drug 
request behaviour, and changing doctors). The reliability analyses revealed that the Aad 
measure (α = 0.897) as well as the Ab measure (α = 0.891) are highly valid. Respondents’ 
perceptions of the drug’s riskiness were also added as a dependent variable in order to 
examine how they could have been influenced by the pre-dispositional and individual 
variables in question. A Multiple Analysis of Variance (MANOVA) was conducted. 
 
1. Main Effects of “Prescription Drug Use” 
The MANOVA revealed significant main effects of “prescription drug use” on the 
participants’ Aad and Ab , their information search behaviour and drug request intentions. 
However, the participants’ prescription drug use did not determine their intentions to 
change doctors if he/she refused to prescribe Arthraid the advertised drug to them. 
Prescription drug use also had a marginally significant effect on the participants’ 
perceptions of the drug’s riskiness, while it had no significant effect on their recognition 







Table 3: MANOVA Results for the Effect of “Prescription Drug Use” 
 
Dependent variable 
Means by group for each D.V 
 
Users (n=28)                 Non-users (n=62) 
      
F 
Aad 4.81 3.87 8.224* 
Ab 4.9 4.17 9.107* 
Risk 4.05 3.39 3.662** 
Recognition 5.43 4.98 0.660 
Additional information seeking  14.93 11.56 13.012* 
 
Drug request 3.32 2.34 18.98* 
Changing doctors 1.469 1.403 0.243 
NOTE: All F-tests associated with (1, 86) df. Significance levels p < .05 (2-tail) indicated by “*” and p < .1 (2-tail) indicated by “**.” 
 
T-test analysis indicated that prescription drug users have a more positive Aad and 
Ab, and lower risk perceptions, than non-users. Also, participants who have taken an 
arthritis prescription drug are more willing to search for additional information about 
Arthraid and request it than those who have not taken an arthritis prescription drug. Both 
prescription drug users and non-users were reluctant to changing doctors if he/she refused 









Table 4: T-test Results for the Effect of “Prescription Drug Use” 
Dependent variable t  p 
Aad 2.787 0.007* 
Ab 3.061 0.003* 




Drug request 4.268 0.000* 
Changing doctors 0.460 0.647 
NOTE: All t-tests associated with (88) df. Significance levels p < .05 (2-tail) indicated by “*” and p < .1 (2-tail) indicated by “**.” 
 
 
2. Main effects of “Cognition” 
A MANOVA revealed a significant main effect of cognition on the respondents’ 
recognition of the ad content only. There was no significant main effect of cognition on 
Aad , Ab  , behavioural intentions, or risk perceptions. (See Table 5) 
Table 5: MANOVA Results for the Effect of “Cognition” 
 
Dependent variable 
    Means by group for each D.V  
High Cognition(n=46)     Low Cognition(n=44) 
 
F 
Aad 3.92 4.43 2.942 
Ab 4.38 4.43 0.028 
Risk  3.59 3.61 0.036 
Recognition 5.83 4.39 8.419* 
Additional 
information seeking  
13.8 12.62 1.668 
Drug request 2.66 3.02 2.381 
Changing doctors 1.377 1.495 0.772 




A t-test analysis indicated that participants with a higher cognition level 
recognized more of the ad’s content than those with a lower cognition level. There are 
three memory components salient throughout the recognition measure: memory of the 
drug’s side effects and precautions; its purpose and benefits; and of the general 
indications for its use and administration.  Multiple t-tests were conducted to investigate 
the differences in the recognition of each of these three memory components across 
varying levels of cognition. Interestingly, the results showed that higher cognition levels 
resulted in a higher recognition of the drug’s purpose and benefits, and directions for use. 
However, there was no significant difference in the recognition of the drug’s side effects 
and precautions, across both levels of cognition (See Table 6). 
 
Table 6: T-Test Results for the Effect of “Cognition” 
Dependent variable t  p 
Overall Recognition 3.222 0.002* 
Recognition of the drug’s 
benefits/purpose 
2.706 0.008* 
Recognition of the drug’s 
directions for use 
2.779 0.007* 
Recognition of the drug’s 
side effects 
1.242 0.218 












3. Interaction Effects 
 
 No significant interaction effects were found (See Table 7 for a description of the 
means and standard deviations by group for each dependent variable). 
 







           Cognition level 
 
    High                           Low 




Rx.Users M = 4.5 
SD = 1.77 
 M = 5.17 
SD = 1.63 
Non-users  M  = 3.63 
SD = 1.46 
 M = 4.11 





Rx.Users  M  = 4.92 
SD = 1.43 
 M = 4.88 
   SD = 1.46 
Non-users   M  = 4.12 
SD = 0.8 
 M = 4.24 





Rx.Users  M  = 6.07 
SD = 1.98 
 M = 4.69 
SD = 2.72 
Non-users  M  = 5.71 
SD = 2.21 
 M = 4.26 
SD = 1.84 
     
Additional information seeking 
(F=0.581) 
(p=0.448) 
Rx.Users M = 15.8 
SD = 1.035 
  M = 13.92 
SD = 1.11 
Non-users M  = 11.8 
SD = 0.72 
 M  = 11.32 
SD = 0.72 




Rx.Users M  = 3.07 
SD = 0.26 
M  = 3.61 
SD = 0.28 
Non-users M = 2.26 
SD = 0.181 
M = 2.42 
SD = 0.181 
NOTE: All F-tests associated with (1, 86) df, and relate to the interaction effect between “Prescription Drug Use” and “Cognition 




4. Covariance Analysis 
Given that cognition declines with age, a Multiple Analysis of Covariance 
(MANCOVA) was run, with age as a covariate, and both “Prescription Drug Use” and 
“Cognition” as the two independent variables. The significant effect of cognition on 
recognition no longer held true when age was controlled for, (F(1, 85) = 2.797, p > .05).  
 Therefore, the sample was segmented into three age categories following the age 
segmentation proposed by Lazer (1986), grouping together those aged between 65 and 74 
as the middle old, between 75 and 84 as the seniors group, and those 85 or more as the 
very old group.  
An ANOVA showed a significant difference across these age groups, in their 
overall recognition of the ad’s content. As shown in table 8, the standard deviation of the 
very old participants’ overall recognition is higher than the standard deviations of the 
middle old and seniors’ overall recognition, which indicates a higher variation in the very 
old participants’ recognition. However, taking into consideration the unequal cell sizes, it 
is reasonable to expect the standard deviation of the very old participants’ overall 
recognition to decrease, as the cell size is increased, which should improve the validity of 
the results found. Furthermore, there was no significant difference across age groups, in 
the participants’ recognition of the drug’s benefits, directions for use, and side effects (p 
> .05) (See Table 8 for a description of the means and standard deviations by age group 













Means and SD of recognition across age groups 
Middle Old (n=56)     Seniors(n=25)      Very old (n=9) 
 
F 
Overall recognition M = 5.41 
SD = 2.096 
  M = 5.08 
SD = 2.06 
       M = 3.44 
   SD = 2.92 
3.175* 
Recognition of the 
drug’s 
benefits/purpose 
 M = 0.67 
SD = 0.26 
  M = 0.61 
SD = 0.38 
 M = 0.44 
SD = 0.47 
1.887 
Recognition of the 
drug’s directions 
for use 
  M = 0.59  
SD = 0.32 
  M = 0.55 
SD = 0.37 
 M = 0.33 
SD = 0.40 
2.246 
Recognition of the 
drug’s side effects 
    M = 0.41 
SD = 0.3 
  M = 0.4 
 SD = 0.3 
  M = 0.28 
SD = 0.29 
0.744 
NOTE: All F-tests associated with (2, 87) df. Significance levels p < .05 (2-tail) indicated by “*.” 
 
 
A Tukey post-hoc test revealed the following comparisons: A significant 
difference was observed in the overall recognition level of the middle old and very old 
respondents (p < .05). The difference in the overall recognition level of the senior and 
very old respondents was marginally significant (p < .1). There was no significant 
difference in the overall recognition level of the middle old and senior respondents  
(p > .05).  
In general, the recognition of the drug’s side effects and precautions was lower 
(Mside.effects = 0.39) than that of its benefits (Mbenefits = 0.63) and administration instructions 
(Mindications = 0.55). These results support the notion of the risk/benefit “trade-off” 







5. The Effect of “Health Status”  
 In order for someone to have taken a prescription medication, he or she must have 
suffered first from the ailment. In contrast, sufferers can be divided into two groups, 
those who use a prescription drug, and those who turn into other remedies (i.e. generic 
drugs, physical activity, natural remedies, etc.). An interest in further investigating the 
differences between these two groups and the group of non-sufferers led to the following 
research question: 
 
RQ3:  How do arthritis sufferers who use a prescription drug (SUFF.USERS), 
arthritis sufferers who do not use a prescription drug 
(SUFF.NONUSERS), and non-sufferers of arthritis (NON-SUFFERERS), 
differ in their recognition, Aad, Ab, and behavioural intentions? 
 
An ANOVA was conducted with the participants’ health status (e.g., whether they 
suffer from arthritis and whether they take an anti-arthritic prescription drug if they do 
suffer from it) as the independent variable. The analysis revealed significant main effects 
of the participants’ health status on their Aad, Ab, additional information search behaviour 
and drug request behaviours. There was a marginally significant effect of the 
participants’ health status on their recognition of the drug’s benefits. However, there was 
no significant effect of health status on the participants’ overall recognition, recognition 
of the drug’s directions for use and side effects. In other words, all three groups 
(SUFF.USERS, SUFF.NONUSERS, and NON.SUFFERERS) equally recognized the 
ad’s claims, specifically those pertaining to the drug’s directions for use and side effects.   
 57 
 
In addition, the participants’ health status did not influence their intention to change 
doctors if he/she refused to prescribe Arthraid the advertised drug to them (See Table 9). 
 





Means by group for each D.V  
 
Suff.Users      Suff.Nonusers    Non-Sufferers 







5.43 5.19 4.88 0.515 
Recognition of the 
drug’s benefits 
0.73 0.54 0.6 2.597** 
Recognition of the 
drug’s directions for 
use 
0.54 0.55 0.57 0.074 
Recognition of the 
drug’s side effects 
0.4 0.47 0.34 1.486 
Aad 4.81 3.86 3.88 3.843* 
Ab 4.9 3.94 4.3 5.536* 
Additional 
information seeking 
14.93 12.3 11.2 7.335* 
Request Arthraid 3.32 2.57 2.22 10.027* 
Changing doctors 1.46 1.52 1.34 0.789 
NOTE: All F-tests associated with (2,87) df. Significance levels p < .05 (2-tail) indicated by “*” and p < .1 (2-tail) indicated by “**.” 
 
 
A Tukey post-hoc test revealed the following comparisons among the sufferers 
who do use a prescription drug and those who do not, and the non-sufferers of arthritis: 
 Sufferers who use a prescription drug recognized more of the drug’s benefits than 
sufferers who do not use a prescription drug (p < .1).  
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 Sufferers who use a prescription drug had more positive Aad than both sufferers 
who do not use a prescription drug (p < .1) and non-sufferers (p < .05). 
 Sufferers who use a prescription drug had more positive Ab than both sufferers 
who do not use a prescription drug and non-sufferers (p < .05). 
 Sufferers who use a prescription drug were more willing to search for additional 
information on the advertised drug than both sufferers who do not use a 
prescription drug (p < .1) and non-sufferers (p < .05). 
 Sufferers who use a prescription drug were more willing to request the advertised 
drug than both sufferers who do not use a prescription drug and non-sufferers  
(p < .05). 
 There was no difference in the recognition of the drug’s benefits of the non-
sufferers on one hand, and both sufferers who use a prescription drug and 
sufferers who do not use one on the other hand (p > .05).  
 There was no difference in the Aad, Ab, additional information seeking and drug 
request behaviours, of the non-sufferers and sufferers who do not use a 










In conclusion, the significant findings are summarized as follows: 
 Sufferers who use a prescription medication have a more favourable Aad and Ab 
than sufferers who do not use a prescription medication and non-sufferers. 
 Sufferers who use a prescription medication are more willing to act in response to 
a DTC ad through additional information search behaviour and specific drug 
requests, compared to sufferers who do not use a prescription medication and 
non-sufferers. 
 The recognition of the drug’s benefits was higher for sufferers who use a 
prescription drug than for sufferers who do not use one. 
 Participants exhibited higher recognition only of the drug’s purpose, benefits, and 
directions for use, at higher cognition levels. 
 The middle old (aged between 65 and 74) had higher overall recognition of the 















The exploratory study attempted to investigate the differences in the hierarchy of 
responses to a DTC ad, between elderly sufferers of arthritis who use a prescription drug, 
sufferers who do not use a prescription drug and non-sufferers. In addition, the effect of 
the elderly’s cognition on their acquisition of the ad information was examined.  The 
following is a discussion of the study’s results. Theoretical, managerial, and policy 
implications are also presented next, followed by an overview of the study’s limitations 
and propositions for future research. 
 
A. HEALTH STATUS AND PRESCRIPTION DRUG USE 
This section discusses the effect of the participants’ health status and prescription 
drug use on their recognition, attitudes towards the ad and brand, behavioural intentions 
and risk perceptions. 
 
1. Effect on recognition of the ad’s claims 
The participants’ health status and prescription drug use did not influence their 
overall recognition of the ad’s claims, and specifically their recognition of the drug’s 
directions for use and side effects. These findings parallel the results of Perri and Nelson 
(1987) who found that prescription drug usage was not a significant predictor of content 
recognition. Nevertheless, the assumed familiarity and involvement (with the product 
class) of sufferers who use a prescription drug are reasonable explanations to their higher 
recognition of the drug’s benefits compared to sufferers who do not use a prescription 
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medication. Analogous results were to be expected when comparing the users to non-
sufferers. Interestingly however, sufferers who use a prescription drug had similar 
recognition of the drug’s benefits to non-sufferers. The unequal cell sizes between these 
two groups and small sample size can serve as reasonable explanations for such 
counterintuitive results.  
 
2. Effect on attitudes and behavioural intentions 
The results of this study give voice to Mehta and Purvis’ (2003) proposition that 
“consumers’ past and current use of prescription drugs might affect their attitudinal, 
behavioural responses to DTC advertising.” The results also extend their finding that 
prescription drug users are more inclined to inquire about a drug, and support Huh and 
Becker’s (2005) findings that prescription drug usage is a significant predictor of 
additional information search, and drug inquiry behaviours. Sufferers who use a 
prescription drug were found to have a more favourable attitude towards the ad and 
brand, and higher intentions to seek additional information about the drug and request it, 
than both sufferers who do not take a prescription medication and non-sufferers of 
arthritis. These findings parallel the results of DeLorme and Huh (2009) and Williams 
and Hensel (1995) who determined a negative relationship between one’s health status 
and their motivation to attend to a DTC ad. The results also support Huh and Becker’s 
(2005) study, in which they found that healthier individuals are less inclined to search for 
additional information on the advertised drug and inquire about it.  
 Interestingly, both sufferers who do not use a prescription drug and non-sufferers 
were less receptive of the DTC ad, and were reluctant to behaviourally respond to it 
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through additional information seeking and drug request behaviours. This finding is 
suggestive of these two groups’ lack of involvement with the product class. Also, as 
revealed by the literature, the influence of DTCA is contingent first and foremost on 
consumer’s perception of DTCA and pharmaceutical manufacturers as reliable and 
trustworthy (Huh and Becker 2005). Consequently, the revelations of the present study 
also suggest that sufferers who do not use an anti-arthritic drug resisted the influence of 
the target ad as a result of their lack of trust in pharmaceutical advertising. 
The preference of the sufferers who do not use a prescription drug for other types 
of arthritis remedies, such as generic drugs, physical activity and natural remedies among 
others, could also justify their resistance to persuasion. Those who have been satisfied 
with their use of a generic drug might be disinclined to consider a more expensive and 
equally effective prescription drug. Those who have resorted to natural remedies or 
physical activity might be unenthusiastic about a chemical remedy. These propositions 
are drawn from the researcher’s interactions with the participants during data collection. 
While some expressed their strong stance against pharmaceutical companies and their 
distrust of such firms, others conveyed their content with physical exercise as an arthritis 
remedy. Both agreed that medical treatments are being over utilized and gave voice to 
what Smith et al. (2002) define as the “medicalization of human problems,” where any 
discomfort or disease, no matter its severity, must be medically treated. Sufferers who 
expressed such opinions believed that the best anti-arthritic medicine is a change in 
lifestyle, starting from one’s diet, activity, etc. All of the above resonates with the 
proposition that the elderly are not as presumed, an easy target of DTCA persuasion. 
Therefore, the findings of the present study support DeLorme and Huh’s (2009) 
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refutation of the elderly’s vulnerability to persuasion and support their view of the elderly 
as active critical thinkers who question the credibility of pharmaceutical firms. 
In addition, DTCA of prescription drugs may influence prescription drug users 
specifically rather than sufferers who do not use a prescribed medication. The latter 
cannot be assumed to be necessarily involved with the ad. Menon et al. (2004) suggest 
that “the future of DTC communication lies in segmenting the consumer market and 
promoting directly to a specific and defined target population.”  The present study 
revealed that prescription drug users, who were more receptive of the advertising 
message, are the most lucrative target market, compared to sufferers who do not use a 
prescription drug. A prescription drug user has a conviction that a prescription 
medication is the best option, and a DTC ad could remind him or her to request a refill of 
the drug. Refill behaviour and adherence to the drug regimen are proposed by Menon et 
al. (2004) as long-term post exposure measures that highlight the effectiveness of a mass 
mediated advertising campaign. Nevertheless, pharmaceutical marketers can attempt to 
convert non-users to become users of anti-arthritic prescription drugs, by presenting what 
the drug brand has to offer above and beyond the competition. 
 Finally, all participants regardless of their health status were unwilling to change 
doctors, if he or she refused to prescribe Arthraid to them. Such a finding further suggests 
that the elderly prefer to rely on their doctor in health care decision making and have 
more trust in his/her opinion, thus supporting the work of DeLorme et al. (2006a) and of 





3. Effect on risk perceptions 
Knowing that being a prescription drug user is an antecedent for high felt 
involvement, it is reasonable to postulate and say that prescription drug users were more 
involved than non-users. However, product class involvement might be a more accurate 
representation of the drug users’ motivation, than advertising message involvement. In 
other words, their involvement may have been directed towards the product or drug rather 
than towards the ad itself.  
Moreover, familiarity and enduring motivation were found to be significant 
precursors of consumers’ motivation to analyze and learn health-related information 
(Moorman 1990). Therefore, although consumers’ domain knowledge about arthritis 
prescription drugs was not measured, it could rationally be assumed that they are familiar 
with the product class, and that their familiarity with arthritis prescription drugs impacted 
their processing of the ad’s content. More specifically, their use of a prescription 
medication could have positively moderated their motivation to attend to the message, 
deemed personally relevant. This is justified by the marginal effect found on risk 
perceptions; those who have taken a prescription drug had lower perceptions of risk. 
Their familiarity with the product class could have alleviated their views of Arthraid as 
an unsafe drug. 
 
B. COGNITION  
 The study revealed only a positive relationship between the participants’ 
cognition and their recognition of the ad’s content. However, a high cognition level 
enhanced the participants’ learning of the drug’s benefits and directions for use only. No 
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difference was observed in learning the drug’s side effects across both levels of 
cognition.  
 Moreover, recognition of the drug’s side effects and precautions was lower in 
general, than that of its benefits and administration instructions. Hence, the participants, 
regardless of their health status and cognitive abilities, appeared to ignore the information 
on Arthraid’s side effects and precautions, supporting the description of such information 
as irritating and distressing. As Morris et al. (1989) noted, consumers engage in a trade-
off when processing risk and benefit information, in both directions. “Accurate 
processing of risk information leads to an inaccurate perception of drug benefits. 
Conversely, when consumers are able to effectively process the benefit information, they 
may not know too much about the risks of the drug” (Menon et al. 2004). 
 However, given that cognition declines with age, the latter was found to have a 
stronger influence on the respondents’ acquisition of the ad’s content.  The very old (aged 
85 or above) had the lowest level of recognition, and hence the most difficulty at 
remembering the information presented in the ad. The middle old (aged between 65 and 
74) were able to learn information about the drug as much as the seniors (aged between 
75 and 84) did. However, both younger groups and more noticeably the middle old were 
able to retain more information than the very old. The results support the Benet et al. 
(1993) proposition that the effect of aging on the elderly’s mental abilities is only 
significant starting the age of 85.  
 Interestingly, the middle old, seniors and very old similarly recognized the drug’s 
benefits, directions for use and side effects. Therefore, age did not determine what 
product claims the elderly better recognized, however, it did influence their overall 
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recognition. Cognition seems to be a more powerful determinant of what product claims 
the elderly recognize, with higher cognition resulting in higher recognition of the drug’s 
benefits and directions for use. 
 It is important to note that overall, the respondents’ recognition level of the ad 
content was low, with an average of five statements correctly recognized out of 10. In 
other words, the elderly were able to retrieve only half of the informational points they 
read in the Arthraid ad. These results are highly suggestive of this age segment’s 
difficulty at learning and using new information, even from print advertising, and support 
the findings of Cole and Houston (1987) that the elderly consumers face encoding 
deficiencies when processing ad information in either print or televised format. 
Abernathy and Adams-Price (2006) give a reasonable explanation to these 
counterintuitive findings; although one would expect a self-paced ad to accommodate for 
the elderly’s memory deficiencies, print ads are hard to remember, for they are 
information-rich, ambiguous, and void of any auditory component.  
 
C. THEORETICAL IMPLICATIONS AND CONTRIBUTIONS 
 This section condenses the theoretical implications and contributions of the 
current study, drawn from the discussion of the results. First, one’s familiarity with the ad 
stimulus or object and his/her intrinsic sources of personal relevance (ISPR) discussed in 
the literature are determinants of his/her motivation to attend to the ad’s message (Celsi 
and Olson 1988; Sujan 1985). In the context of the current study, the prescription drug 
users’ acquaintance with anti-arthritic drugs, and their personal need for such a remedy, 
contributed to their information processing motivation and involvement with the ad. 
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Second, given that sufferers who do not use a prescription drug were less receptive of the 
DTC ad compared to sufferers who use a prescription drug, the results support Huh et 
al.’s (2004) view of the elderly as active receivers of DTCA information. Concomitantly, 
given that sufferers who do not use a prescription drug had similar responses to the DTC 
ad as the non-sufferers, the findings of this study support DeLorme et al.’s (2006a) view 
of the elderly as passive receivers of advertising information since they primarily trust 
their physician (vs. DTCA). 
Third, the elderly actively participate in their health care decision making and are not as 
presumed - a vulnerable target of persuasion, a finding that supports DeLorme and Huh’s 
(2009) refutation of the elderly’s susceptibility to DTCA influence. The present study 
revealed that even sufferers who are not using a prescription medication exhibit 
resistance to DTCA despite them suffering from the ailment and needing a remedy. The 
results also suggested that the elderly ultimately trust their health care provider more than 
mass media advertising. Therefore, it can be rationally assumed that the elderly are 
protected against deceptive pharmaceutical advertising practices. 
Fourth, the decline in the elderly’s mental abilities is most prominent in their late 80s. 
The present study found that the elderly’s learning decrement mainly increased at the age 
of 85, supporting the results of Benet et al. (1993). In general however, knowledge of the 
advertising claims was low, which is highly suggestive of learning deficiencies in the 
elderly, even when information is communicated in an internally-paced format 
(Abernathy and Adams-Price 2006; Cole and Houston 1987). Therefore, the results do 
not support the findings of Phillips and Sternthal (1977) and Roedder John and Cole 
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(1986) that the elderly do not encounter learning difficulties when exposed to print 
advertising.  
 
D. MANAGERIAL IMPLICATIONS 
Findings from this exploration suggest important implications for managers of 
pharmaceutical companies and advertisers. First, it is imperative that they pretest their 
ads and investigate the audience’s reactions to them, taking into consideration the 
variations in responses that are due to individual and pre-dispositional variables. The ad’s 
effectiveness lies not only in its ability to move the prescription drug users to act, but also 
in its ability to persuade the sufferers that do not use a prescription drug, and to move 
them to behaviourally respond to ads. Therefore, although it is difficult, brand 
differentiation is extremely important, especially in late stages of a drug’s life cycle. 
Furthermore, advertisers could increase the attention and processing motivation of 
non-sufferers by cautioning them that they could develop the featured ailment at some 
point in the future, which should draw their attention to the ad (Menon et al. 2004). 
Moreover, advertisers should keep in mind the elderly’s cognitive and physical 
deficiencies, and develop their advertisements accordingly. Abernathy and Adams-Price 
(2006) for example, advance the use of an FAQ format instead of the traditional drug 
insert, as a simpler, more reader-friendly and less technical way of presenting the drug’s 
selling points and side effects to an elderly segment. Marketers should also be careful 
when targeting consumers aged 85 or older, given that starting this age their learning 
decrement increases.  
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 Advertisers should also refrain from overloading their advertisements with 
information. They should decrease the amount of product attributes mentioned, and keep 
the visual elements of the ad (images, etc. ) simple, thus adapting their ads to the learning 
difficulties of the elderly and to their physical deficiencies (i.e., poorer vision), 
(Abernathy and Adams-Price 2006). The body copy and pictures should also be 
consistent, as their synergistic combination can enhance the memorability of ads (Macias 
and Lewis 2003). 
In addition, DTCA of prescription drugs is best at accelerating the introduction of 
and building primary demand for a new or improved drug, and for maintaining 
consumers’ loyalty and brand awareness towards a mature drug, before it loses its patent 
protection. Roth (2003) found that awareness of a drug brand was increased as a result of 
a DTC ad exposure. Sheffet and Kopp (1990) also believe that firms are capable of 
increasing the total market size of their drug in its early stages of a product life cycle, by 
informing consumers of this new available treatment through advertising. The authors 
also advise marketers to emphasize the benefits of the drug brand over its competitors, 
when the drug reaches its mature stage. Baukus (2004) also believe that creating strong 
brand name recognition for prescription drugs is extremely important in competing 
generic brands and differentiating the prescription medication as a better and safer 
alternative, and consequently maintaining market share. 
Finally, pharmaceutical companies are encouraged to maintain their advertising to 
professional health care providers alongside DTCA, given that the elderly still prefer to 
rely on their physician’s opinion in health care decision making (Maddox 1999; Xie 
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2009). Pharmaceutical companies should also position themselves as honest and reliable 
sources in their DTCA campaign, in an attempt to increase consumers’ trust in them. 
 
E. PUBLIC POLICY IMPLICATIONS 
It is imperative for policy makers to realize that DTCA is limited in its power to move 
consumers, especially if they resort to other remedies than brand name prescription drugs. 
In general, the elderly are unwilling to insist on a drug and contest their doctor’s opinion. 
Their reliance primarily on a professional medical source for health care decisions assists 
them from being inappropriately influenced by a DTC ad. As Huh and Becker (2005) 
stated, “[…] contrary to what many opponents fear, when exposed to DTC ads, 
consumers do not blindly rush to their doctors to get a prescription for the advertised drug 
but try to find more information from other sources.”  Hence, the notion that DTCA has 
led consumers to behave as unlearned professionals was not supported in this study in the 
context of an elderly sample. 
 
F. STUDY LIMITATIONS 
 The study’s methodological shortcomings involve a lack of external validity, due 
to survey respondent bias and sample representativeness of the general population. As a 
consequence, the findings must be carefully generalized to other populations. That is not 
to mention that the study used a convenience sample of a small size (n=90) and skewed 
towards being a female sample (although females are overrepresented in this age 




Moreover, although there was an attempt to create a natural research setting, the 
study imperatively lacked mundane realism. As Celsi and Olson (1988) put it, “the 
advertisements were presented within an artificial context void of the editorial and story 
content of a real magazine.” That is not to mention that the advertisements designed for 
the purpose of this research, were not as creatively aesthetic and appealing as 
professional advertisements. 
In addition, the cognitive measures used in this study were subtests drawn from 
the WAIS, which is a more comprehensive and extensive clinical instrument for the 
measurement of adult intelligence, consisting of ten core subtests.  However, due to 
restrictions in the execution of the present study, administering the whole test was not 
feasible. Finally, the recognition measure should be complemented by an unaided free 
recall measure, or an aided recall test. 
 
G. AVENUES FOR FUTURE RESEARCH 
 Based on the study’s limitations, avenues for future research are proposed. 
Even though it is difficult to execute and time consuming, future researchers are advised 
to use a random sample, to ensure a representative sample of the population. They are 
also advised to include a recall measure of the ad’s content, in addition to a recognition 
measure. Long term post-exposure effects ought to be considered. Researchers could 
include a distraction task between the ad exposure and the measurement of responses, to 
examine their durability. Also, the study’s external validity could be enhanced by testing 
the effectiveness of repeated ads, since consumers are exposed to the same ad repeatedly, 
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in reality. Evidently, this type of research is more time-consuming, complicated, and 
sensitive to hypothesis guessing and respondent withdrawal.  
Longitudinal research could be undertaken in a comparative context across 
different age segments. A comparative study might also revolve around different 
advertising mediums to compare consumers’ responses across broadcast, print and online 
DTCA. Researchers may also use different ailments rather than just one. 
In addition, researchers could make this study’s procedure more realistic by 
embedding the stimulus ad in an editorial content, in order “[to allow] other stimuli (ads 
and articles) to compete for subjects’ attention” (Laczniak et al. 1989). The authors also 
suggest randomly distributing factors such as product class involvement across 
experimental conditions. Knowing that product class involvement might interfere with 
advertising message involvement (AMI), and that the effect of one should be 
distinguished from the other, Kavadas (2003) proposed to screen prescription drug users 
versus non-users beforehand, and then prime them each with high and low involvement 
manipulations. Laczniak and Muehling (1993) on the other hand suggested allocating 
participants into involvement groups based on the median split of their index involvement 
scores, as a more natural grouping way that bypasses the artificiality of imposed 
involvement manipulations.  
Moreover, it is important that future researchers conduct in-depth interviews with 
focus groups of elderly consumers, to ask them about their DTCA related experiences, 
feelings, reactions, and opinions, so as to give voice to the survey results. The following 
speculation is proposed: one of the reasons underlying the non-users’ resistance to the 
ad’s persuasive attempts is their aspiration to project a positive self-image, where they 
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deliberately try to be more immune to media persuasiveness, and perceive others as more 
susceptible to it. Researchers could better examine the possibility of perceived third-
person ad effects as determinants of consumers’ reactions to the ad, in an extensive 
interviewing process (DeLorme et al. 2006). 
Future research should also include a measure of the participants’ familiarity with 
the drug which might justify their responses. In the context of the present research, 
participants who are familiar with the product class might have had an unfavourable 
reaction towards the ad if he or she thought Arthraid has no added value. 
In addition, other researchers could investigate the influence of the respondents’ 
“experience, media use, media literacy, relationship with physicians, and access to other 
information sources” on their perceptions of a DTC ad (DeLorme and Huh 2009). “Trust 
in media is essential for any DTC ad to have a persuasive effect on the consumer” 
(Menon et al. 2004). A measure of the respondents’ trust in DTCA, distinguished from a 
measure of their attitude towards DTCA, should also be included in future research. As 
previously mentioned, a lack of confidence in DTCA and pharmaceutical companies 
might justify the elderly’s resistance to the influence of this type of advertising, even 
among sufferers. Gönül et al. (2000) and Menon et al. (2002) found a negative 
relationship between one’s trust in their doctor or pharmacist, and his/her attitude towards 
DTCA. Researchers could use Choi and Lee’s (2007) scale to determine the credibility 
views of the participants, vis-à-vis DTC advertising in different media (i.e., television, 
magazine, newspaper, radio, and the Web). Respondents were asked to rate these 
mediums on a thirteen-item, seven-point semantic differential scale, with endpoints 
accurate/inaccurate, trustworthy/untrustworthy, and profound/superficial.  
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Furthermore, researchers could examine how personality traits of vulnerable 
segments of the elderly population, such as “those who have a trusting personality” and 
“are seriously ill and desperate for a cure,” might affect their processing and evaluation 
of DTC ads (DeLorme and Huh 2009). Baukus (2004) states that pictures, and not only 
advertising copy, can convey “unrealistic expectations” that are exaggerated by a 
recipient who is in desperate hope for a cure.  
Finally, the elderly’s need for cognition (NFC) might also be a possible variable 
influencing their motivation to process and evaluate DTC ads. A higher NFC about the 



















The findings of this study suggest that elderly prescription drug users evaluate a 
mass advertised prescription drug ad and the featured brand more favorably than non-
users. Subsequently, they are more willing to act in response to an ad exposure through 
additional information seeking behaviour and specific drug requests. Interestingly, 
sufferers who do not use a prescription medication were similar in their responses to non-
sufferers. Both groups were less receptive of the DTC ad and negatively responded to it, 
compared to sufferers who use a prescription medication. These results lead to the 
conclusion that prescription drug use is a stronger determinant of DTCA persuasiveness 
and of its behavioural outcomes than is the mere role of being a sufferer. Hence, a 
distinction should be made between targeting sufferers of an ailment and targeting 
prescription drug users. The latter are expected to find more personal relevance in mass 
mediated prescription drug ads and subsequently, react more favorably to them.  All 
participants however, regardless of their health status were unwilling to change doctors if 
he/she refused to prescribe the advertised drug to them, which is suggestive of the 
elderly’s preferred reliance on their physician’s opinion. 
Moreover, elderly respondents with higher cognition had better recognition of the 
ad content, specifically of the drug’s benefits and directions for use than did those with 
lower cognition. However, average recognition was generally low, and the effect of the 
participants’ cognitive abilities on recognition no longer held true when age was 
considered. Further analysis showed that age differences are attributed to the elderly’s 
learning deficiencies which start at the age of 85. These results are highly suggestive of 
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the need for advertisers to tailor their ads in accordance with the elderly’s cognitive 
needs.  
In conclusion, this study advises managers and advertisers to simplify the 
technical language and information, design and visual presentation of a DTC ad, 
especially when targeting an older segment. Moreover, this unique form of advertising is 
effective at introducing a new drug brand and at maintaining recognition of a mature 
drug, among prescription drug users. Brand differentiation is encouraged to capture the 
attention of sufferers who are not using a prescription medication. Brand managers are 
also encouraged to build trust with the audience, and convey a responsible and reliable 
image, through their DTCA campaign. 
Finally, policy makers are informed that the elderly are not as vulnerable as 
presumed and they are not passive recipients. Their defiance of DTCA persuasiveness 
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APPENDIX A: Research Questions of the Experimental Study 
 
The original experimental study attempted to manipulate the amount of risk 
disclosure in the target ad and the involvement of the participants in the advertising 
message. Drawing from theories of fear appeal, the latter induce anxiety and tension and 
trigger the recipient’s defense mechanism, if the level of fear is above the optimal level. 
Higher involved consumers are expected to become less involved with the ad, at higher 
levels of risk disclosure, in an attempt to cope with the incoming information. 
Subsequently, having paid less attention to the ad, and having lost their motivation to 
process the ad, highly involved consumers will recognize fewer advertisements claims at 
higher levels of risk disclosure, compared to lower levels (Keller and Block 1996). 
Furthermore, highly involved participants will recognize fewer claims than low 
involved participants, who are expected to be less defensive and retain their receptiveness 
of ad messages.  
In addition, Burton and Lichtenstein (1988) found a positive relationship between 
attitude towards the ad, and attitude towards the brand, where the former influences the 
other. Based on the premise of a threshold level of fear appeal, the relationship between 
consumers’ attitudes towards the ad and brand, and the level of risk disclosure, will 
consist of an inverted U-shape, regardless of involvement levels. To further elaborate, 
consumers’ evaluation of the ad and brand will be negative at both low and high levels of 
risk disclosure. Their attitude formation will reach its peak at balanced levels of risk and 
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benefit information. These expectations are based on the premise that a high risk ad will 
induce tension in the receiver, and that a low risk ad will be perceived as uninformative 
and unbalanced.  Finally, consumers’ behavioural intentions will be formed based on 
their evaluation of, and attitude formation towards the ad and brand. A positive 





















APPENDIX B: Involvement Manipulation 
 
 Highly involved participants were asked to imagine that a relative suffering from 
arthritis had asked them to look for information concerning arthritis remedies, following 
Laczniak and Muehling’s (1993) proposition that a high involvement manipulation 
involves “creating a situation in which subjects are asked to role-play so as to encourage 
processing the stimulus as though it were personally relevant to them.” Participants in the 
low involvement condition were asked to browse through the ads as if they were flipping 
through a magazine at home. Less attention and lower feelings of personal relevance 
were expected as an outcome of these instructions. 
 
High involvement: 
In this study we are interested in your perception of advertisements for prescription 
drugs. This type of research is important towards understanding what should be permitted 
in advertising of medications. Your opinion is essential in the development of this type of 
advertising which inevitably affects the type and quality of healthcare information 
available to you and your loved ones.  
Instructions:  
Imagine that a close family member has just told you that they appear to be suffering 
from arthritis. They are extremely uncomfortable, and are experiencing a series of 
severely unpleasant symptoms. You are sorry to see a close relative suffer in such a way 
and this person has asked you to look for information on possible treatments for arthritis 
before they consult their physician.  
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Please read each ad carefully looking for information that may help your relative. 




In this study we are interested in your perception of advertisements for prescription 
drugs. This type of research is important towards understanding what should be permitted 
in advertising of medications. Your opinion is essential in the development of this type of 
advertising which inevitably affects the type and quality of healthcare information 
available to you and your loved ones. 
Instructions: 
In this booklet, there are four prescription drug ads. We would like you to look at each 
ad as if you were seeing it in a magazine at home. Though the present situation is 
different from being at home, please keep these instructions in mind as you browse 
through the ad booklet. 










APPENDIX C: Risk Manipulation (See Figure 3) 
 
The risk disclosure manipulation varied the amount of risk information but held 
fixed the amount of benefit information presented in the ad. The low risk, balanced, and 
high risk ads had two, five, and eight risk indications, against five promotional points. 
Therefore, the balanced ad or control condition, featured five benefits and five side 
effects/precautions, presented in an equally detailed manner. The control ad was a 
starting point, for the development of the low and high risk ads. The three statements 
added to the high risk condition supplement those included in the control condition, but 
were characterized by a heightened severity of side effects, as they referred to fatal 
stroke, ulcers, and stomach bleeding. Hence, the ads contained specific risk information, 
knowing that consumers have a preference for specific and detailed presentation of side 
effects, and perceive such communication to be more informative than general 












Figure 3: Description of Risk Manipulation 




-Need for only one 180-mg Arthraid per 
day. 
 
-Up to 24h relief from arthritis related 
pain, inflammation, and stiffness. 
 
- Arthraid helps improve your daily 
physical activity. 
 
-Arthraid can be taken with or without 
food. 
 
-The incidence of severe stomach 
problems such as ulcers is less than that 
seen in other NSAIDs. 
Low risk ad 
-Side effects such as fluid retention 
-Several days for side effects to     
disappear 
Control (Balanced ad) 




-Adverse reactions with some other drugs 
-Heart attack if prolonged use 
High risk ad 




-Adverse reactions with some other drugs 
-Heart attack if prolonged use 















APPENDIX D: Pretests 
 
 A first pretest was undertaken with 18 individuals to evaluate the likeability of six 
mock prescription drug ads. The fictitious drugs featured in the filler and target ads, 
echoed the benefits and risks of actual drugs that treat similar conditions. Fictitious (vs. 
real) drug names were used, to control for the familiarity effect. The ads that elicited the 
most positive attitudes were chosen.  
 A second pretest was conducted, carried out as the actual experiment. The sample 
consisted of 18 individuals, aged above 65. This final pretest included a manipulation 
check of the independent variables, risk disclosure and advertising message involvement. 
It is important to note here that the Zaichkowsky (1985) involvement scale was adjusted 
to account for reverse coding.  A one-way analysis of variance (ANOVA) and a t-test 
were performed in order to measure if the risk and involvement manipulations, 
respectively, were successful. Both analyses generated significant results. For the risk 
manipulation, the ANOVA yielded an F(2, 15) = 16.167, p < .05. For the involvement 










APPENDIX E: Manipulation Checks of the Actual Experiment 
 
A one-way analysis of variance (ANOVA) served as a manipulation check for the 
risk variable. The results yielded an F(2, 87) = 6.707, p < .05. However, the post-hoc 
tests revealed that only a difference between the low and high risk ads was significant 
(p<0.05), rendering the risk manipulation only partially significant.  
A t-test conducted as an involvement manipulation check yielded t(88) = -0.524, p > .05. 
Therefore, the involvement manipulation was insignificant.  
 It is reasonable to assume that the risk manipulation was unsuccessful, as a result 
of the elderly’s processing deficiencies. Based on an observation of the descriptive 
statistics, the participants only recognized half of the advertisement claims which 
translates into a difficulty at learning new content. Therefore, it can be postulated that the 
elderly were unable to recognize significant differences in risk disclosure, and could not 
appropriately evaluate the ads’ risk level for a time after exposure, due to limitations in 
learning and remembering new content.  
The following are potential justifications for the unsuccessful involvement 
manipulation; the participants are healthy, they do not get exposed to ads frequently, or 
they prefer to rely on other sources of information (DeLorme and Huh 2009). All three 
characteristics lead to a lack of motivation to attend to a pharmaceutical ad. 
 The heterogeneity of the sample is also strongly believed to be one of the main 
reasons underlying the insignificant manipulation checks. As Davis and French (1989) 
noted, the elderly segment is the most heterogeneous of all, with regards to its cognitive 
and physical abilities, and psychological characteristics. Phillips and Sternthal (1977) 
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also stated that physical, psychological, and social factors, contribute to the 
multidimensionality of this age group. Variations due to age are not the only element that 
accounts for the heterogeneity of the sample. The fact that it is a convenience sample (vs. 
a random sample) further augments that reality. 
In investigating the reasons underlying the insignificant manipulations checks, a  
re-examination of the questionnaire revealed that the post-exposure measure of  
involvement that was intended as a manipulation check, did not serve as one. One of the 
defensive strategies employed by the message receiver when exposed to a fear appeal ad, 
or in the context of the present study, a high risk ad, involves denying the personal 
relevance of the message. Hence, there is a high possibility that the involvement 
manipulation was successful, but the varying levels of risk moderated the participants’ 
level of post-exposure involvement. One of the potential shortcomings of the original 
design was the omission of a pre-exposure measure of involvement that may have served 
as a better manipulation check. The Zaichkowsky (1985) scale used in this study could 
serve as the pre-exposure measure. The  items used by Celsi and Olson (1988), and the 
message attention manipulation check employed by Laczniak et al. (1989) are proposed 
as better post-exposure measures (See Table 10). These measures touch more deeply on 
the respondents’ felt involvement and on their processing motivation during exposure.  
Finally, a different and enhanced high involvement manipulation could be 
recommended. The instructions could tell the reader that he or she could be at risk of 
developing the target ailment in the future (Menon et al. 2004). An increase in the 




Table 10: Proposed Post-Exposure Involvement Manipulation Checks 










•The message in the ad was 
important to me. 
•The ad didn’t have anything 
to do with me or my needs. 
  
 
Seven-point bipolar items 
with endpoints “strongly 
agree” (1) and “strongly 
disagree” (7) for the first 
item, and the opposite for 
the second item.  
 
The average of the items 







•How much attention did you 
pay to the written message in 
the ad?  
•How much did you notice 
the written message in the 
ad?  
•How much did you 
concentrate on the written 
message in the ad?  
• How involved were you 
with the written message in 
the ad?  
• How much thought did you 
put into evaluating the 
written message in the ad? 
Seven-point scale with 
endpoints "None" (1) and 
"Very Much" (7).  
 
The sum of the scores on the 
five items results in an 
index of message attention. 
 
Cronbach alpha = 0.952 
 
 









APPENDIX F: Consent Form 
 
                                                      CONSENT TO PARTICIPATE IN: 
                          “Research on Pharmaceutical Advertising to Older Consumers”                                                                                                        
This is to state that I agree to participate in a program of research being conducted by 
Joyce Sarkis, of the Department of Marketing of Concordia University.  
 
A.PURPOSE 
I have been informed that the purpose of the research is to examine my responses to 
various drug advertisements.             
B.PROCEDURE              
The experiment will be conducted at Concordia University. I will browse through a 
booklet containing ads, at my own pace and then be required to complete a questionnaire, 
which should take approximately 30 minutes. I will be given the option to know the 
results of the study once it is completed. All data and results arising from this study will 
be presented in aggregate format only, which means that my responses cannot be tracked 
back to me. I am also aware that I will be compensated $15 for my time and participation 
in this study. I am also aware that if at any time I feel uncomfortable during the study, I 
have the right to withdraw simply by raising my hand.  
C.RISKS AND BENEFITS 
I am aware that there are virtually no threats or risks involved in completing this study. 
This study will benefit researchers to understand my reactions to Direct-to-Consumer 
drug ads. It will also benefit policy makers to establish better drug advertising 
regulations. 
D.CONDITIONS OF PARTICIPATION               
• I understand that I am free to withdraw my consent and discontinue my participation at 
any time without negative consequences. 
• I understand that my participation in this study is CONFIDENTIAL. 
• I understand that the data from this study may be published.  
 
I HAVE CAREFULLY STUDIED THE ABOVE AND UNDERSTAND THIS AGREEMENT. I 
FREELY CONSENT AND VOLUNTARILY AGREE TO PARTICIPATE IN THIS STUDY. 
  








APPENDIX G: Manipulation Checks of the Independent Variables 
 
Zaichkowsky (1985) involvement measure: 
Please complete the following questions related to the Arthraid anti-arthritic drug ad. 
Make sure you check every single scale; do not omit any.  
To me the advertisement for Arthraid is:  
         Important  __ _  :  __ _   : ___   :  ___  :  ___   :  ___   : ___   Unimportant 
 
 Of no concern to me  __ _  :  __ _   : ___   :   ___ :  ___   :  ___   : ___  Of  concern to me 
 
Does not matter to me __ _  :  __ _   : ___   :   ___ :  ___   :  ___   : ___   Matters to me 
 
             Boring   __ _  :  __ _   : ___   :   ___ :  ___   :  ___   : ___    Interesting 
 




The Arthraid ad included information of the possible risks involved in taking the 
medication as well as the potential benefits. In comparing the riskiness of the drug to its 
benefits, overall, would you say the drug in this ad is: 
 
       1                 2              3         4       5    6             7 
Extremely     Moderately       Slightly   Balanced Slightly      Moderately      Extremely              
risky              risky            risky                            beneficial     beneficial        beneficial 
 
In comparing the safety of this drug to its lack of safety, would you say the drug in this ad is: 
 
      1    2  3                  4      5     6             7 
Extremely   Moderately       Slightly   Balanced Slightly        Moderately     Extremely    






APPENDIX H: Dependent Measures 
Recognition measure: 
Please indicate if you do recall seeing the following statements in the Arthraid drug ad.  
1) This drug relieves stiffness.            
        Yes            No               Don’t Know 
2) This drug relieves arthritis pain for up to 24 hours.   
        Yes             No              Don’t Know 
3) This drug relieves inflammation.          
        Yes             No              Don’t Know 
4) This drug might cause adverse effects such as nausea.     
        Yes    No           Don’t Know 
5) Tablets must be taken once weekly.           
       Yes            No              Don’t Know 
6) Arthraid can only be taken with food.         
       Yes            No              Don’t Know           
7) Arthraid is available by prescription only.        
       Yes            No              Don’t Know 
8) This drug might cause side effects such as fluid retention.         
       Yes            No              Don’t Know  
9) This drug might cause side effects such as headaches.     
        Yes               No            Don’t Know  
10) Prolonged use of this drug may cause liver disease.        
        Yes               No            Don’t Know  




The Attitude towards the Ad measure (Holbrook and Batra 1987) 
The purpose of this section is to measure your overall attitude towards the drug ad 
Arthraid. Please respond to each of the six scales, never putting more than one check 
mark for each scale. 
   I dislike the ad __ _  : __ _  : ___   : ___ :  ___   : ___   : ___   I like the ad 
 
 
I react favorably __ _  : __ _  : ___   : ___ :  ___   : ___   : ___  I react unfavorably  
      to the ad                  to the ad 
 
    I feel positive __ _  : __ _  : ___   : ___ :  ___   : ___   : ___   I feel negative  
  towards the ad           towards the ad 
  
  The ad is bad    __ _  : __ _  : ___   : ___ :  ___   : ___   : ___    The ad is good 
 
 
The Attitude towards the Brand measure (Laczniak and Muehling 1993): 
 
The purpose of this section is to measure your attitude towards the advertised product 
Arthraid. Based on the information given in the ad, do you believe this prescription drug 
is: 
Very bad __ _  : __ _  : ___   : ___ :  ___   : ___   : ___   Very good 
 
Valuable __ _  : __ _  : ___   : ___ :  ___   : ___   : ___   Worthless 
 
   Very favorable __ _  : __ _  : ___   : ___ :  ___   : ___   : ___   Very unfavorable 
 
Of low quality__ _  : __ _  : ___   : ___ :  ___   : ___   : ___   Of high quality 
 
     I very much dislike  __ _  :  __ _  :  ___   :   ___ :   ___   :   ___ :   ___   I very much like  







Behavioural intentions measure (Everett 1991): 
Please respond to each of the following questions by circling one of the numbers that best 
corresponds to your answer. 
If you were to see the ad for Arthraid, the arthritis medication, in a magazine: 
 
1) Would you read the ad carefully? 
         1                         2                        3                        4                        5           
        I definitely           I probably            Might               I probably        I definitely  
         would not            would not        or might not            would               would              
 
2) Would you tell your doctor you had seen the ad? 
        1                         2                        3                        4                        5           
        I definitely           I probably            Might               I probably        I definitely  
         would not            would not        or might not            would               would         
                 
3) Would you discuss Arthraid’s effectiveness with your doctor? 
 
     1                         2                        3                        4                        5           
        I definitely           I probably            Might               I probably        I definitely  
         would not            would not        or might not            would               would                                   
 
 
4) Would you ask your doctor to prescribe any brand of arthritis remedy to you? 
                      
     1                         2                        3                        4                        5           
        I definitely           I probably            Might               I probably        I definitely  
         would not            would not        or might not            would               would         
 
 
5) Would you ask your doctor to prescribe Arthraid to you? 
 
       1                         2                        3                        4                        5           
        I definitely           I probably            Might               I probably        I definitely  
         would not            would not        or might not            would               would         
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6) Would you change doctors if your doctor refused to prescribe it to you? 
 
                     
      1                         2                        3                        4                        5           
        I definitely           I probably            Might               I probably        I definitely  
         would not            would not        or might not            would               would    
      
7) Would you ask your friends or family if they have been prescribed this drug? 
 
     1                         2                        3                        4                        5           
        I definitely           I probably            Might               I probably        I definitely  
         would not            would not        or might not            would               would         
              
8) Would you call the drug’s 1-800 number? 
             1                         2                        3                        4                        5           
        I definitely           I probably            Might               I probably        I definitely  
         would not            would not        or might not            would               would         
 
9) Would you visit the drug’s website? 
 
             1                         2                        3                        4                        5           
        I definitely           I probably            Might               I probably        I definitely  





APPENDIX I: Demographic Variables 
Please respond to the following questions pertaining to demographic variables: 
Female               Male 
Age_____ 
First Language:   English      French        Other language______________ ___ 
-Have you worked/Are you working in the healthcare industry?         Yes      No 
-Do you or have you ever suffered from arthritis?                     Yes                 No 
-Does anyone in your family suffer from arthritis?                    Yes                 No 
-Have you ever received prescribed medication for arthritis?    Yes                 No 
-If yes, are you taking any now?     Yes               No 
-Please indicate your level of education:  
 Less than High School 
  High School Diploma 
 Some university 
  University Degree (Bachelors) 










APPENDIX J: Additional Measures 
Attitude towards print advertising (Shavitt, Lowrey and Haefner 1998): 
Please respond to each of the following questions, by circling one of the numbers that 
best corresponds to your answer.  All questions pertain to ADVERTISING IN PRINT 
MEDIA. 
1) In general, do you like or dislike advertising in print media? 
                             1                    2                    3                   4                  5           
                        Strongly         Dislike        Neither like       Like         Strongly  
                         dislike                               nor dislike                 like 
 
2) I like to look at most advertising I am exposed to. 
                              1                    2                    3                   4                  5           
                        Strongly         Dislike        Neither like       Like         Strongly  
                         dislike                               nor dislike                 like 
 
3) Most advertising insults my intelligence. 
                              1                    2                    3                   4                 5           
                        Strongly        Disagree     Neither agree     Agree      Strongly  
                          agree                             nor disagree    agree 
 
4) How often do you feel offended by advertisements?  
                          
      1                    2                     3                  4                   5           
                         Always       Frequently      Sometimes      Rarely          Never 
 
 
5) How often have you felt misled by advertisements? 
      1                    2                     3                  4                   5           
                         Always       Frequently      Sometimes      Rarely          Never 
 
 
6) Most advertising is informative. 
 
                              1                    2                    3                   4                 5           
                        Strongly        Disagree     Neither agree     Agree      Strongly  
                          agree                             nor disagree    agree 
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7) In general, I feel that I can trust advertising. 
                              1                    2                    3                   4                 5           
                        Strongly        Disagree     Neither agree     Agree      Strongly  
                          agree                             nor disagree    agree 
 
 
8) How often do you use information from advertising to help make your purchase 
decisions? 
      1                    2                     3                  4                   5           
                         Always       Frequently      Sometimes      Rarely          Never 
 
 
9) In general, how confident are you in using information you see in an ad, to make 
a purchase decision? 
            
                            1                    2                     3                  4                     5           
                     Not at all         Slightly       Somewhat    Moderately    Extremely 
                     confident        confident      confident      confident       confident 
 
10) How comfortable are you in seeking additional information on an item directly 
through an address or phone number in an advertisement, for example, by using a 
1-800 number? 
                    
                            1                     2                      3                       4                       5                 
                      Not at all         Slightly          Somewhat       Moderately      Extremely 
                   comfortable    comfortable    comfortable      comfortable     comfortable 
 
11) What is your assessment of the amount of regulation that the government 
currently places on advertising? 
 
                            1                    2                     3                  4                     5              
                        Way          Too much      About right    Too little           Way                                               
                    too much                                          too little 
 
 
12) Advertising regulation should be done by the advertising industry through its 
member associations rather than by the government. 
                     
 1                    2                    3                   4                 5           
                      Strongly        Disagree     Neither agree     Agree      Strongly  




13) I think the government should put less effort into regulating the content of the 
advertising I see. 
 
                            1                    2                    3                   4                 5           
                        Strongly      Disagree     Neither agree     Agree      Strongly  










































Attitude towards DTCA (Perri and Nelson 1987) 
 
Please respond to each of the following questions by circling one of the numbers that best 
corresponds to your answer. Choose only one response for each question.  
1) Prescription drug information should come only from your doctor or 
pharmacist. 
                     1                     2                         3                         4                      5           
                Strongly        Disagree           Neither agree         Agree             Strongly  
                disagree                                   nor disagree                        agree 
 
2) Prescription medicines for serious medical problems should not be 
advertised to consumers. 
                       1                    2                         3                         4                      5           
                Strongly        Disagree           Neither agree         Agree             Strongly  
                disagree                                   nor disagree                        agree 
                     
3) I think advertisements for prescription drugs provide me with information I 
have a right to know. 
                        1                    2                         3                         4                      5           
                Strongly        Disagree           Neither agree         Agree             Strongly  
                disagree                                   nor disagree                        agree                         
 
4) Prescription drug advertisements could protect consumers from doctors and 
pharmacists who are not well informed. 
                        1                    2                         3                         4                      5           
                Strongly        Disagree           Neither agree         Agree             Strongly  
                disagree                                   nor disagree                        agree  
 
5) Prescription advertising gives me information that I think my doctor or 
pharmacist probably would not tell me.  
 
                        1                    2                         3                         4                      5           
                Strongly        Disagree           Neither agree         Agree             Strongly  
                disagree                                   nor disagree                        agree 
 
6) Consumers want to know more about the medicines they are taking. 
 
                        1                    2                         3                         4                      5           
                Strongly        Disagree           Neither agree         Agree             Strongly  
                disagree                                   nor disagree                        agree 
